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Abstract Duchenne muscular dystrophy is caused by muta-
tions in the dystrophin gene and is characterized by
progressive muscle wasting. A number of Duchenne patients
also present with mental retardation. The dystrophin protein
is part of the highly conserved dystrophin-associated glyco-
protein complex (DGC) which accumulates at the neuromus-
cular junction (NMJ) and at a variety of synapses in the
peripheral and central nervous systems. Many years of
research into the roles of the DGC in muscle have revealed
its structural function in stabilizing the sarcolemma. In
addition, the DGC also acts as a scaffold for various signaling
pathways. Here, we discuss recent advances in understanding
DGC roles in the nervous system, gained from studies in both
vertebrate and invertebrate model systems. From these
studies, it has become clear that the DGC is important for
the maturation of neurotransmitter receptor complexes and for
the regulation of neurotransmitter release at the NMJ and
central synapses. Furthermore, roles for the DGC have been
established in consolidation of long-term spatial and recog-
nition memory. The challenges ahead include the integration
of the behavioral and mechanistic studies and the use of this
information to identify therapeutic targets.
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Introduction
Duchenne muscular dystrophy (DMD) is a common X-
linked, fatal genetic disorder characterized by progressive
muscle wasting [1]. The disease was named after the
French neurologist G.B.A. Duchenne who, in the mid-
1800s, described patients that suffered not only from
muscular dystrophy but also from mental retardation [2]. A
major advancement in understanding the underlying cause
of DMD came in 1987, when dystrophin was identified as
the protein that is absent in DMD patients [3, 4]. Mental
retardation occurs in approximately one third of DMD
patients and is apparently dependent on the specific
location of the mutation within the dystrophin gene (in
mammals called the DMD gene) [5]. Despite more than two
decades of intense clinical and basic research into the DMD
disease process and the interactions and roles of the
dystrophin protein, a cure for the disease remains elusive
and treatments palliative. Thus, much remains to be learned
about the basic biological roles of the dystrophin protein in
the musculature and in the brain.
The DMD gene is one of the largest genes in the human
genome, spanning 2.3 Mb [6]. It has three upstream
promoters that control expression of full-length dystrophin
Dp427 and four internal promoters which regulate expres-
sion of the short dystrophin isoforms, Dp260, Dp140,
Dp116, and Dp71 (reviewed at www.dmd.nl; Table 1;
Textbox 1 in “Appendix”). The complexity of DMD gene
expression, which results in multiple transcripts and protein
isoforms, has made understanding the functions of individ-
ual dystrophin protein isoforms difficult. Dp427 has an
amino-terminal actin-binding domain, and Dp427, Dp260,
Dp140, and Dp116 have a variable number of spectrin-like
repeats that are predicted to form triple-helical rod-like
structures. Dystrophin proteins invariably bear a number of
protein–protein interaction domains, some of which are
bound by other dystrophin-associated glycoprotein complex
(DGC) members: a WW domain, a cysteine-rich region
containing a ZZ domain, and a highly conserved carboxy-
terminal region including a coiled-coil domain.
Dystrophin is predominantly expressed in the muscula-
ture and the nervous system (Fig. 1, Table 2, and references
therein). More specifically, the three distinct Dp427
variants that are transcribed from different promoters and
have distinct first exons are expressed in skeletal muscle
(Dp427M), throughout the brain (Dp427B) and in Purkinje
cells (Dp427P), respectively. Dp260 is expressed in the
retina, Dp140 in brain and kidney, Dp116 in the peripheral
nervous system, and Dp71 is uniformly expressed, but most
prominently present throughout the mammalian brain
(reviewed in [7]; Fig. 1; Table 2). In mammals, there are
two proteins which are significantly homologous to
dystrophin, utrophin [8], and the much shorter dystrophin-
related protein 2 (DRP2) [9]. Utrophin is more ubiquitously
expressed compared to dystrophin, hence its name. It is
found in developing skeletal and smooth muscle, the
nervous system, the lung, kidney, liver, spleen, and stomach
[10, 11].
Many components of the DGC have been identified,
including the dystrobrevins (DB-α and DB-β), the syntro-
phins (α1, β1, β2, γ1, and γ2), dystroglycan (DG-α/β),
the sarcoglycans (SG-α, SG-β, SG-γ, SG-δ, SG-ε, and SG-
ζ), and sarcospan [10, 12]. Together with dystrophin, these
proteins form a large, molecularly heterogeneous cluster
[13], known as the DGC, that differs in composition
depending on the tissue or organs where the components
are expressed (reviewed in [10, 14–16]; Fig. 1; Table 2).
The proteins of the DGC are highly conserved between
species, although there are fewer homologs and isoforms in
the lower vertebrates, such as zebrafish, and in the
invertebrates, Caenorhabditis elegans and Drosophila
(Table 1).
Due to the complex and variable composition of the
DGC, it is difficult to assign a general function to this
transmembrane complex. However, in all organisms studied
thus far, the different DGCs localize to the plasma
membrane (reviewed in [12]). In muscle, the DGC has
long been thought to be required for the stabilization of the
plasma membrane by linking the actin cytoskeleton to the
extracellular matrix [17]. Disruption of the DGC caused by
the absence of dystrophin consequently renders the sarco-
lemma susceptible to mechanical damage during contrac-
tion and ultimately results in muscle degeneration. More
recently, it has been established that the DGC also functions
as a scaffold for proteins involved in signaling, including
neuronal nitric oxide synthase (nNOS), phosphoinositol
triphosphate 2, calmodulin, and growth factor receptor-
bound protein 2 (grb2; reviewed in [18]). Additional
evidence supports the involvement of the DGC in the extra-
cellular signal-regulated kinases (ERK)/mitogen-activated
protein kinase (MAPK) signaling cascade [19], epidermal
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signaling [21]. Moreover, it has been shown that the DGC
is required for neurotransmitter receptor and ion channel
clustering and in maintaining calcium (Ca
2+) homeostasis
[22, 23].
Since the 1990s, the role of the DGC in brain function
has also become the topic of extensive clinical and basic
research; however, the mechanisms of action of the
different dystrophin isoforms in brain are still largely
unknown [5]. Interestingly, a patient was recently described
carrying a mutation in the carboxy-terminal region of the
DMD gene, who suffered from a mental disorder but
showed no signs of muscle weakness [24]. This finding
raises the possibility that there may be more patients with
cognitive impairments caused by alterations in dystrophin
expression or function and demonstrates the important role
for dystrophin and its associated proteins in the brain
( r e v i e w e db y[ 25]). Moreover, mutations in the gene
encoding an enzyme that glycosylates α-dystroglycan,
protein O-mannosyltransferase (POMT) 1, have been
associated with a range of muscular dystrophies that are
often accompanied by severe mental retardation and ocular
abnormalities [26–28]. In recent years, novel gene therapy
strategies, such as antisense oligonucleotide-mediated
exon-skipping, have been directed toward restoring dystro-
phin expression in muscle fibers of DMD patients [29].
Promising results have been obtained in a phase I clinical
trial [30]. While the application of such approaches in the
brain will likely be more challenging, these reports validate
the need for preclinical studies to establish the agents and
means of delivery required for treatment of DMD-
associated nervous system deficits.
Mammalian DMD models, such as the mdx mouse,
which lacks the three full-length dystrophin Dp427 iso-
forms, have been studied most extensively. However, it is
now becoming clear that invertebrates such as C. elegans
and Drosophila can also serve as models to study the
fundamental and likely conserved functions of the DGC
[31–33]. The reduced functional redundancy of the DGC
members [31], the genetic tools available, and the ease of
transgenic manipulation render these invertebrate animal
models useful. Both the worm and the fly have only a
single dystrophin/utrophin ortholog, and their functions
may therefore reflect roles played by both dystrophin and
utrophin in mammals. Drosophila exhibits muscle degen-
eration and a reduced lifespan when the expression of
certain DGC members are reduced or absent [21, 34–37].
C. elegans lacking DGC components also display severe
dystrophy of the musculature, but only in a genetically
sensitized background where muscle differentiation is
impaired [38]. These findings illustrate the relevance of
these models for DMD.
This review focuses on recent insights into the specific
roles of the DGC at the synapse gained from studies using
mouse and invertebrate animal models. First, we summarize
what is known about the function of the DGC at the
neuromuscular synapse with emphasis on results obtained
from mouse, C. elegans and Drosophila. We then describe
the roles of DGC members in central synapses in the brain
and the retina and how disruption of the complex may
Table 1 Compilation of the known DGC components in human/mice, zebrafish, C. elegans, and Drosophila
DGC member Species
Human/mice (www.dmd.nl) Zebrafish [180]
(www.zfin.org)
C. elegans [33]
(www.wormbase.org)
Drosophila [32]
(www.flybase.bio.indiana.edu) Protein (gene)
Dystrophin Long isoforms: Dp427
(M, B, P)
Long isoform: a 400-kD
dystrophin ortholog
Dystrophin-like
protein (dys-1)
Long isoforms: DLP1-3
Short isoforms: Dp260,
Dp140, Dp116, Dp71 (DMD)
Short isoform: Dp71
(dmd)
Short isoforms: Dp205,
Dp186, Dp117 (Dys)
Utrophin a-, b-, g-Utrophin (utrn) Utrophin (utrn) [181]
DRP2 Dystrophin-related protein
(DRP2)
DRP2 [181] ––
Dystrobrevin α-Dystrobrevin (DTNA) α-Dystrobrevin (dtna) Dystrobrevin (dyb-1) Dystrobrevin-like (Dyb)
β-Dystrobrevin (DTNB) β-Dystrobrevin (dtnb)
γ-Dystrobrevin (dtng) [181]
Dystroglycan α/β-Dystroglycan (DAG1) α/β-Dystroglycan (dag1) Dystroglycan (dgn-1) Dystroglycan (Dg)
Sarcoglycan α-, ε-, β-, γ-, δ-,
ζ-Sarcoglycan (SCGA-Z)
α-, β-, δ-ε-, γ-,
ζ-Sarcoglycan
α-,β-, δ/γ-
Sarcoglycan
(α-, β-, δ/γ-sgn)
Sarcoglycan-α, Sarcoglycan-β,
Sarcoglycan-δ (Scgα, Scgβ,
Scgδ)
Sarcospan Sarcospan (SSPN),
(microspan in mice)
Not determined ––
Syntrophin α-, β1-, β2-Syntrophin Not determined β1-Syntrophin (stn-1) Syntrophin-like 1 and
Syntrophin-like 2 (Syn-1, Syn-2) γ1-, γ2-Syntrophin γ-Syntrophin
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4 Mol Neurobiol (2010) 41:1–21cause cognitive impairment. Our focus is on the possible
signaling pathways interacting with the DGC that may be
important for the development or maintenance of peripheral
and central synapses.
Roles of the DGC at the Neuromuscular Junction
In this section the involvementofthe DGCatthe mammalian
neuromuscular junction (NMJ) is discussed in receptor
clustering, synaptic transmission, and its participation in a
number of important signaling cascades acting at the NMJ,
such as the agrin/muscle-specific kinase (MuSK)/rapsin,
nNOS, and Ca
2+/calmodulin-dependent protein kinase II
(CAMKII)-mediated signaling pathways. In the following
Sections, insights obtained in DGC NMJ function using
the C. elegans and Drosophila invertebrate model systems
which reveal novel roles for dystrophin in neurotransmitter
clearance and in the regulation of neurotransmitter release,
respectively, are reviewed.
The Involvement of the DGC in AChR Clustering, Synaptic
Transmission, and Signaling at the Mammalian NMJ
AChR Density, Junctional Folds, and Transmission
Are Reduced at DGC-Deficient NMJs
The six families of proteins encompassing the DGC can be
divided into three subcomplexes: (1) a cytoplasmic com-
plex comprised of dystrophin (or utrophin), dystrobrevin
and syntrophin, (2) the transmembrane dystroglycan com-
plex, and (3) the sarcoglycan–sarcospan complex (reviewed
in [1, 18, 25, 39, 40]). Dystrophin is expressed at the
sarcolemma of mammalian skeletal muscle and is also
found to accumulate at the troughs of the postsynaptic
membrane where it colocalizes with voltage-gated sodium
channels [41]. Dystrophin is only consistently detected at
the mammalian NMJ after postnatal day 7 [42]. Utrophin,
however, accumulates at the postsynaptic side of the
neuromuscular junction during early postnatal development
as part of a protein complex, the utrophin glycoprotein
complex (UGC; Fig. 1b), which includes the syntrophins,
dystrobrevins, sarcoglycans, sarcospan, and dystroglycan
[43]. Dystroglycan interacts with the more general struc-
tural and signaling components of the NMJ, including
agrin, laminin, and rapsyn and also associates with clusters
of acetylcholine receptors (AChRs) at the crests of the
junctional folds [41, 42]. In addition, the adaptor protein
ankyrin B is required for localizing the DGC at the
mammalian postnatal NMJ [44].
Much has been learned about the mechanisms that
underlie the development and function of the vertebrate
NMJ (reviewed in [45–47]). A synapse is formed with a
highly specialized presynaptic membrane, the active zone,
opposing a postsynaptic density enriched in AChRs
(in vertebrates) in the crests of the junctional folds and
voltage-gated sodium channels in the troughs. Several
signaling pathways involved in organizing the initial stages
of NMJ formation have been, at least in part, elucidated.
One such pathway includes agrin, a heparin sulfate
proteoglycan that is released from the motor neuron to
activate the postsynaptic tyrosine kinase receptor, MuSK.
Engagement of MuSK leads to a second messenger cascade
resulting in the clustering of the AChRs, the major
Fig. 1 Differential DGC complex composition at mammalian muscle,
NMJ, CNS, and retina. The compositions of the different DGC/UGC
complexes that have been reported [1, 7, 10, 14–16, 25, 32, 39, 182]
to be present in vertebrate muscle (a), at the NMJ (b), in brain (c), and
at the retina (d) are shown. a In skeletal muscle, the N-terminal actin-
binding domain and specific spectrin repeats in the central rod of
dystrophin bind to costameric F-actin. The cysteine-rich region and
the C terminus of dystrophin establish the link with the DGC through
binding to β-dystroglycan [183] and α-dystrobrevin2, respectively
[184, 185]. β-Dystroglycan is linked to the extracellular α-
dystroglycan, which, depending on the tissue, links laminin α2 along
the sarcolemma. In addition, β-dystroglycan associates with δ-
sarcoglycan by which the sarcoglycan–sarcospan complex is stabilized
at the sarcolemma [186]. The DGC can bind four syntrophins (α1 and/
or β1), which in turn recruit sodium channels and signaling
molecules, such as nNOS, via their PDZ domains. nNOS can also
associate with dystrophin directly via its spectrin-like repeats [72]. b
At the NMJ, a similar complex, the UGC, is formed, in which
dystrophin can be replaced by A-utrophin and α-dystrobrevin1
replaces α-dystrobrevin2 [185, 187]. After postnatal day 7, dystrophin
can be detected at the rat NMJ, and therefore, a DGC can also be
formed. These proteins bind α-syntrophin, which is present at crests
and troughs of the junctional folds. β2-Syntrophin is mainly localized
to the troughs. α-Dystroglycan not only binds the laminins β2, α4,
and α5 but also the proteoglycans agrin and perlecan. Perlecan is
necessary for synaptic localization of acetylcholine esterase, which is
involved in termination of cholinergic neurotransmission [188]. The
synaptic localization of β-dystroglycan is dependent on the presence
of rapsyn [189, 190], which is important for stabilization of AChR
clusters and linkage of these clusters to the UGC at the crests of the
junctional folds (reviewed in [51]). β-Dystroglycan binds to utrophin.
c In the brain, the DGC consists of at least four main components,
dystrophin or utrophin, dystroglycan, dystrobrevin, and syntrophin,
with variations in the isoforms present depending on the cell type. The
composition of the sarcoglycan–sarcospan complex is not known for
this tissue, but δ- and ε-sarcoglycan are detected in brain samples. The
neuronal DGC consists of a full-length dystrophin isoform (Dp427)
bound to β-dystrobrevin and dystroglycan, which in turn associates
with presynaptic neurexin-α. The complex also contains α1- and γ1-
syntrophin. d In the retina (reviewed in [155]), different dystrophin
isoforms are expressed; Dp427, Dp260, Dp140, and Dp 71. Dp260 is
highly specific in the photoreceptor terminals of retina [119]. Utrophin
is present in the end-feet fraction of Müller glial cells [166]. Dp71
and/or utrophin and α-dystroglycan from Müller cells bind actin and
laminin, respectively [191]. The sarcoglycan complex which is
composed of δ-, γ-[ 191], β-, and ε-sarcoglycan, and sarcospan
[182] is bound to β-dystroglycan and dystrobrevin. β-Dystrobrevin is
expressed at the outer plexiform layer (OPL) of the retina, while α-
dystrobrevin1 is located at the inner limiting membrane (ILM)[ 134].
Syntrophins, α1 and β1, interact with the carboxy-terminus of
dystrophin [192]
R
Mol Neurobiol (2010) 41:1–21 5neurotransmitter receptors present at the NMJ. Recently, it
was reported that postsynaptic Lrp4 and MuSK act as
coreceptors of agrin [48, 49]. Furthermore, Tid1 was
identified as a downstream effector of agrin/Lrp4/MuSK-
induced AChRs clustering and maintenance, possibly by
modulating the organization of the subsynaptic cytoskele-
ton [50]. The pre- and postsynaptic specializations required
for establishment and maintenance of NMJ synapse
function are spatially aligned, at least in part, by these
interactions.
Rapsyn, an effector protein of MuSK signaling, is also
required for AChR clustering. Rapsyn physically links the
AChRs to the UGC, and this interaction seems to be
required for AChR stabilization and maturation of the NMJ
(reviewed in [51]). Specifically, when agrin binds to the
extracellular region of dystroglycan, it localizes to the
NMJ, where it participates with other proteins to cluster
the AChR via its intracellular association with rapsyn.
While the UGC complex as a whole seems to be
required for stabilizing AChR clusters, rather than being
responsible for their initial formation, several components
of the UGC, i.e., α-dystrobrevin and α-syntrophin, are
also involved in other signaling events at the NMJ
(discussed below).
Table 2 Compilation of the known expression domains of DGC components of human/mice and Drosophila
DGC member Species
Human/mice Expression domain Drosophila Expression
domain (embryo)
Dystrophin Dp427 Muscle (M), brain (B), Purkinje
cells (P), retina
DLP1 Visceral mesoderm
Dp260 Retina DLP2 Visceral mesoderm,
musculature,
mesectoderm
Dp140 Fetal tissues, brain glia, CNS,
retina, kidney
DLP3 Adult
Dp116 Schwann cells (brain and spinal cord) Dp205 Pericardial cells, VNC,
visceral mesoderm
Dp71 Ubiquitous, but most prevalent in brain
(microvascular glial and gyrus
dentatus cells), retina, perivascular
astrocytes, liver
Dp186 CNS, midgut
a-Utrophin NMJ, fetal muscle, muscle, pia mater,
choroid plexus, astrocytes, renal
glomerulus
Dp117 Musculature, VNC
Utrophin in retina
b-Utrophin Vascular endothelial cells ––
g-Utrophin
(homolog of Dp116)
Sensory ganglia, brain
DRP2 CNS (brain), Schwann cells
Dystrobrevin α-Dystrobrevin Skeletal and cardiac muscle, NMJ,
brain, retina, heart, lung
Dystrobrevin-like Musculature, VNC,
brain, midgut
β-Dystrobrevin Retina
Dystroglycan α/β-Dystroglycan Most tissues Dystroglycan Musculature, brain, VNC
Sarcoglycan α-, β-, γ-, and
δ-Sarcoglycan
Skeletal and cardiac muscle Sarcoglycan-α, Sarcoglycan-β,
Sarcoglycan-δ
CNS, gut, musculature
β-, γ-, δ-Sarcoglycan in mouse retina
ε-Sarcoglycan Smooth, skeletal and cardiac muscle,
lungs, liver, kidney, brain, Schwann
cells, retina
ζ-Sarcoglycan Brain, skeletal muscle, kidney,
spleen, pancreas
Sarcospan Sarcospan Skeletal and cardiac muscle, retina –
Syntrophin α1-, β1-,
β2-Syntrophin
Skeletal and cardiac muscle, NMJ,
brain, retina, lung, kidney, liver,
pancreas, testes
Syntrophin-like 1 Brain, VNC
γ1-Syntrophin Brain, general expression Syntrophin-like 2 Mesoderm
γ2-Syntrophin
The data reviewed in this table are taken from [1, 7, 10, 14–16, 25, 32, 39, 182]
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NMJ function came from the observation that knockout
mice of dystroglycan, utrophin, α1-syntrophin, or α-
dystrobrevin display reduced AChR densities at the NMJ
[52–56]. These mice also have a reduction in the number of
the junctional folds, a morphological defect that might
possibly underlie the altered receptor density. The reduction
of postsynaptic folds and reduced AChR density is further
exacerbated in the double knockout mdx;utrn mouse which
lacks both utrophin and dystrophin, indicating that dystro-
phin also plays an important role at the NMJ [40, 57, 58].
Most of these studies were done in mice older than 7 days
of age at which stage both dystrophin and utrophin can be
detected at the NMJ. Mice deficient in α-dystrobrevin show
a 70% reduction in AChR density, and the remaining
receptors are irregularly distributed in aggregates as the
distinction between crests and troughs of junctional folds
becomes less apparent [59, 60]. Importantly, the initial
formation of the NMJs is normal in these mice, but their
postnatal maturation is compromised, resulting in the
described abnormalities.
Few electrophysiological studies of the DGC/UGC-
deficient NMJs have been reported. However, utrn knock-
out mice exhibit decreased miniature endplate current
amplitudes [54], consistent with the reduction in postsyn-
aptic acetylcholine (ACh)-dependent neurotransmitter re-
ceptor clusters observed. Interestingly, miniature endplate
potentials were also found to be decreased in mdx mice,
while these mice display only subtle changes in junctional
fold morphology and AChR density [61, 62]. The structural
roles of the UGC and DGC in stabilizing NMJ receptor
clusters and junctional folds may therefore be independent
of their roles in regulating synaptic transmission.
DGC Participation in Signal Transduction Pathways
at the Mammalian NMJ
While the role of the DGC in stabilizing the sarcolemma
during repeated cycles of contraction and relaxation is well
studied, much less is known about the involvement of the
complex as a scaffold for signaling pathways. α-
Dystrobrevin knockout mice were found to exhibit muscle
degeneration in the absence of apparent structural deficits of
the sarcolemma [59], suggesting that dystrobrevin may play
roles in signaling. Since these mice also show a displacement
of nNOS from the membrane, it was hypothesized that
impaired nitric oxide (NO) signaling likely contributed to the
observed dystrophy [59].
A second clear indication for possible roles of the DGC
in signaling was suggested by the observed physical
association of the DGC with numerous signaling molecules
such as calmodulin, CaMKII, protein kinase A (PKA),
phosphoinositide 3-kinases (PI3K), grb2, son of sevenless,
and Ras in addition to nNOS. Thirdly, since several DGC
pathway members contain potential phosphorylation sites
for serine/threonine or tyrosine kinases, DGC function and
activation might be regulated by phosphorylation. Indeed,
dystrophin is a target of CaMKII-, MAPK-, p34-cdc2
kinase-, and casein kinase-dependent phosphorylation in
vivo (reviewed in [18]). In cell culture, phosphorylation of
dystrophin has been shown to alter its affinity for actin and
syntrophin [18].
Direct evidence for a functional role of tyrosine
phosphorylation of DGC proteins has only been established
for dystrobrevin. α-Dystrobrevin mutated at a presumptive
tyrosine phosphorylation site failed to fully rescue the NMJ
defects in the dystrobrevin knockout mouse [63]. Dystro-
brevin is also a target of the serine/threonine kinase PKA
[64], a protein implicated in synaptic plasticity, learning,
and memory acquisition [65]. Thus, phosphorylation of
dystrobrevin at several distinct sites likely modulates its
activity during synaptic remodeling.
The DGC actively participates in signaling pathways that
are associated with cell survival, cellular defense, and cell
growth in a variety of tissues mediated by not only the
aforementioned molecules calmodulin, PI3K, and nNOS
but also by MAPK, protein kinase B (akt), and the insulin
receptor pathway (reviewed in [18]). Here, two examples of
pathways relevant for DGC function in the nervous system
will be discussed, i.e., DGC participation in nNOS
signaling and in Ca
2+-mediated homeostasis.
nNOS NOS, which generates NO, plays roles in a number
of cellular signaling pathways which, among others,
include those involved in apoptosis, in the protection
against ischemia, and in regulating vascular tone [66].
While these more general cellular functions are relevant for
NOS involvement in the progression of DMD [67], there is
also evidence for a more specialized role of NOS in
modulating UGC function at the NMJ. NO also acts as both
an antero- and retrograde modulator of synaptic transmis-
sion at central synapses [68]. While the role of NO in the
cerebellum and hippocampus has been studied in great
detail, little is known about its possible interactions with the
DGC at these synapses.
Indications that nNOS and the UGC/DGC play interde-
pendent roles at the NMJ are supported by the following
observations, (1) nNOS is physically associated with the
UGC [69], (2) nNOS levels are substantially reduced and
nNOS is dislocated from the postsynaptic membrane of
DMD patients and in mdx and α-syntrophin mutant mice
[67, 70] and (3) NMJ abnormalities in the mdx mouse (and
to a lesser extent in α-syntrophin null mutant mice) can be
fully rescued upon expression of a nNOS transgene in
muscle [71]. However, no such rescue was observed in the
α-syntrophin/β1-syntrophin double knockout mouse, indi-
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nNOS to the NMJ [71]. It has been recently established that
dystrophin itself can also serve as a scaffold for nNOS
sarcolemmal targeting [72].
How do alterations in NO levels result in changes in
UGC function? Increased NO levels lead to the activation
of guanylate cyclase and elevated production of cyclic
guanosine monophosphate (cGMP) [73], which subse-
quently affects contractile function, glucose metabolism
[74], and Ca
2+ mobilization in muscle fibers [75]. nNOS
also acts as an effector of agrin-induced postsynaptic
differentiation at the NMJ (reviewed in [76, 77]). In brief,
changes in NO and cGMP levels are sufficient to modulate
the activity of a number of protein kinases that in turn
modify the interaction of the UGC with actin, thereby
affecting postsynaptic differentiation. The rod-like region of
the dystrophin and utrophin proteins contain potential
protein kinase G (PKG) phosphorylation sites, while
potential protein kinase C (PKC) phosphorylation sites are
located near the actin-binding sites [78]. Depending on
which site is phosphorylated, F-actin binding to dystrophin
and utrophin is promoted (PKG) or inhibited (PKC).
According to one proposed model [77], agrin-induced
increases in NO/cGMP stimulate PKG and inhibit PKC,
resulting in increased interaction of dystrophin and utrophin
with actin which results in stabilization of AChR aggre-
gates at the NMJ. Another target of NO, the Src family
kinases, then phosphorylates the β-subunit of AChRs,
which promotes their binding to rapsyn and association
with other AChRs [51].
Can muscular degeneration in DMD patients be
explained solely by a reduction in nNOS levels? This is
unlikely, since NOS knockout mice do not display overt
dystrophy [79]. However, since increased NO production
results in enhanced utrophin expression [80] and treatment
of mdx mice with a nNOS substrate, L-arginine, also
increases utrophin levels and its membrane localization
[81], clinical manipulation of nNOS levels in the muscle is
considered a potential starting point for therapeutic inter-
vention [82].
Ca
2+ signaling and homeostasis Ca
2+ levels in dystrophic
muscle are thought to be increased due to disruption of the
sarcolemma and abnormal activation of Ca
2+ leak channels
[83]. It is not clear whether the changes in intracellular Ca
2+
levels and disrupted Ca
2+ homeostasis observed in
dystrophin-deficient muscle are a cause or a result of the
pathogenic processes, such as apoptosis and oxidative
stress, that occur in dystrophic muscle [83, 84]. It is
generally thought, however, that the elevated Ca
2+ levels
will eventually elicit Ca
2+-dependent proteolysis via the
activation of calpains and other Ca
2+-dependent proteases.
In this section, Ca
2+ involvement in apoptosis and necrosis
of dystrophic DMD fibers is not further discussed. Instead,
potential roles for the DGC in the regulation of Ca
2+
homeostasis in muscle and at the NMJ under normal
physiological conditions are reviewed.
A first insight into a role of the DGC in Ca
2+-mediated
signaling came from the findings that two of the DGC
proteins, i.e., dystrophin and syntrophin, physically interact
with calmodulin [85] (reviewed in [18]) and that calmod-
ulin activity is reduced in dystrophin-deficient muscle
fibers [86]. Calmodulin is a Ca
2+-binding protein that
regulates the activity of many Ca
2+-sensitive enzymes and
acts as a sensor of Ca
2+ levels in the cell. Calmodulin is
likely to regulate binding of dystrophin/utrophin to actin
[87], while the Ca
2+/calmodulin dependent kinase, CaM-
KII, actively phosphorylates both dystrophin and syntro-
phin [88]. Dystrophin’s interaction with syntrophin is
inhibited upon phosphorylation [88], further indicating the
regulatory function that CaMKII exerts on DGC activity. In
addition, it has been shown that both CaMKII and
dystrophin are required for maintaining appropriate levels
of neurotransmitter release at the NMJ in Drosophila [89,
90], although at present it is not clear whether they act in
the same or parallel pathways.
The DGC also regulates the activity of several Ca
2+
channels. Changes in mechanosensitive Ca
2+ channel
function in mdx muscle fibers, measured by cell-attached
patch-clamp recordings, revealed that the probability of
these channels being open was increased, presumably
leading to increased Ca
2+ influx [91]. Changes in ACh
neurotransmitter receptor aggregation caused by the disor-
ganization of the membrane-associated cytoskeleton have
been proposed to account for the disturbed Ca
2+ homeo-
stasis and increased Ca
2+ leakage into dystrophin-deficient
muscle [22]. Evidence supporting this hypothesis include
the observations that AChR and voltage-gated L-type Ca
2+
channel aggregates display unusual physical interactions in
dystrophic muscles, which may result in the abnormal Ca
2+
influx observed at these sites [22, 92]. Since channel
activity measurements vary significantly between different
reports, possibly depending on the tissues used, i.e.,
cultured myotubes versus muscle fibers, or the type of
channels studied, a defined role for the DGC in regulating
Ca
2+ channel activity is far from clear.
Dystrophin Regulates Cholinergic Transmission
at the C. elegans NMJ
The highly conserved C. elegans dystrophin ortholog, dys-
1, was first identified in 1998 [93]. In contrast to mammals,
the worm usually has one ortholog for each of the six DGC
gene families [33]. For example, it has a dystrophin gene,
but no utrophin, DRP2,o rsarcospan genes, single
8 Mol Neurobiol (2010) 41:1–21dystrobrevin and dystroglycan genes, and three sarcoglycan
and two syntrophin orthologs (Table 1). Furthermore, the C.
elegans dystrophin gene encodes only one protein isoform
[94]. The reduced potential for functional redundancy has
made C. elegans and other genetically tractable inverte-
brates, such as Drosophila, attractive models to study the
individual roles of each DGC member.
dys-1 loss-of-function mutants display a characteristic
behavioral phenotype: They are hyperactive, bend their
head inappropriately when moving forward, and tend to
hypercontract [93]. Muscle degeneration is observed only
when the dys-1 mutation is placed into sensitized back-
grounds with reduced expression levels of the worm ortholog
of the myogenic factor, MyoD, which is required for muscle
differentiation, or reduced egl-19 Ca
2+ channel function [38,
95]. dys-1 mutants, however, display hypersensitivity to
ACh and exhibit reduced ACh-esterase activity, indicating a
role for dystrophin in cholinergic synaptic transmission at
the worm NMJ [93, 96]. The loss of other worm DGC
members, i.e., dystrobrevin or syntrophin, also gives rise to
increased cholinergic activity [97].
A subsequent report revealed that inactivation of snf-6,a
gene encoding a ACh transporter in C. elegans, results in
an almost identical hyperactivity phenotype to that seen in
dys-1 mutants [98]. Moreover, snf-6 was found to bind to
stn-1, the β1-syntrophin ortholog expressed in the muscle,
and snf-6 expression is lost from the NMJ of both dys-1
and stn-1 mutants [98]. As observed for dys-1, the snf-6
mutation in combination with a mutation of MyoD results
in muscle degeneration. Thus, inefficient clearing of ACh
from the synaptic cleft, due to both a reduction of esterase
activity and the loss of the ACh transporter at the DGC
mutant NMJ, likely accounts for the behavioral phenotypes
observed. Furthermore, it may also contribute to the muscle
degeneration observed in DGC sensitized mutant back-
grounds. Whether altered cholinergic transmission underlies
the dystrophic phenotype in DMD patients remains to be
investigated, although increased sensitivity to ACh has
been reported for human cultured myotubes derived from
DMD patients [99].
Dystrophin Regulates Glutamatergic Transmission
at the Drosophila NMJ
Drosophila Dystrophin Is Required to Maintain Muscle
Integrity
Genomic analyses and expression studies indicate that the
Drosophila dystrophin gene encodes three full-length
(DLP1-3) and three short dystrophin isoforms (Dp186,
Dp205, and Dp117) [32, 94, 100, 101]. DLP2, which is
expressed in the musculature throughout development, is
most closely related to the mammalian Dp427 isoform.
Similarly to C. elegans dys-1 mutants, but unlike mutations
in the human Dp427 isoform, Drosophila Dys
DLP2 E6
mutants do not display obvious muscle degeneration.
However, electrophysiological analyses revealed that neu-
rotransmitter release is increased at the larval NMJ in these
mutants [90].
The short Drosophila dystrophin isoform Dp117 is also
expressed in the musculature [37]. Interestingly, muscle
degeneration was observed in larvae, when all dystrophin
isoform expression levels, or Dp117 specifically, were
reduced in muscle by transgenic RNA interference [37].
In adult flies, progressive muscle degeneration and im-
paired climbing ability were observed when dystrophin or
dystroglycan expression was reduced [21]. The dystrophin
isoform-specific mutant studies suggest that the Drosophila
DLP2 protein, which accumulates at the postsynaptic side of
the larval NMJ [90], is likely functionally analogous to
utrophin at the mammalian NMJ and required for regulating
synaptic transmission. The mechanisms by which Dp117
maintains muscle integrity are not yet clear as this isoform
lacks an apparent actin-binding domain. Generation of
classical Dp117 mutants and identification of Dp117 protein
expression domains should shed further light on its roles.
Further evidence for a role for Drosophila dystrophin in
muscle function comes from a study that described an age-
dependent disruption of the myofibrillar organization of the
myocardium in dystrophin mutants lacking the large
isoforms, accompanied by reduced cardiac performance
and lifespan [36]. Progressive impairment of locomotive
ability, disrupted flight muscles, and reduced cardiac
function and lifespan were also observed in flies lacking
δ-sarcoglycan [34]. Furthermore, in larvae that express
reduced levels of dystroglycan or lack POMT1 or POMT2,
the protein O-mannosyltransferases required for dystrogly-
can glycosylation in vivo, abnormalities in muscle attach-
ment, muscle contraction, and muscle membrane resistance
are reported [35, 102]. In summary, the requirements for
dystrophin, dystroglycan, POMT, and sarcoglycan in main-
taining muscle integrity in flies illustrate the usefulness of
this invertebrate as a model system for the study of
muscular dystrophies.
Does a DGC Exist in Drosophila?
Although in general the orthologs of the mammalian DGC
complex are highly conserved in Drosophila (Table 1), little
is known about whether they form DGC-like complexes.
No biochemical analyses of dystrophin-containing protein
complexes derived from Drosophila tissue preparations or
transfected cells have been reported to date. Perhaps the
strongest evidence for the existence of a DGC-like protein
complex comes from antibody colabeling experiments for
multiple members of the DGC at the larval NMJ, the central
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laminin colocalize in repeating stripes at sarcomeres [35],
suggesting the existence of a T-tubule DGC-like complex,
similar to that which is present in vertebrate cardiac muscle.
Similarly, dystrophin and dystrobrevin are expressed in
overlapping domains at the larval NMJ and in the CNS (S.
P., L.G.F., J.N.N, unpublished), while dystrophin and
dystroglycan have also been shown to colocalize at the
postsynaptic side of the NMJ [103]. Genetic experiments
have further indicated that at the NMJ, dystroglycan
controls the synaptic localization of dystrophin and laminin
[102, 103]. While direct biochemical data are currently
lacking, together these data are consistent with the
existence of DGC-like complexes at the Drosophila NMJ.
The Dystrophin Isoform DLP2 Modulates Neurotransmitter
Release at the NMJ
Drosophila larvae that lack the large DLP2 dystrophin
isoform exhibit elevated levels of evoked neurotransmitter
release at the NMJ [90]. Electrophysiological analyses of
DLP2 mutants showed that the resting muscle membrane
potential in Dys
E6 DLP2 larvae and the depolarization of the
muscle caused by spontaneous vesicle release from nerve
terminals (miniature amplitude) are unaffected [90]. This
suggeststhatthe postsynapticreceptorfieldisnotfunctionally
altered in the mutant. An insight into dystrophin function at
the NMJ was revealed by analysis of the effects of evoked
stimulation. DLP2 mutants display significantly higher levels
of muscle depolarization as compared to control animals
indicativeofanincreasedreleaseofpresynapticglutamate.As
DLP2 is expressed and required in the muscle [90], this
finding indicates that the absence of a postsynaptic dystro-
phin isoform results in changes in presynaptic function.
Possible explanations for the observed increased neuro-
transmitter release at the DLP2 mutant NMJ are (a) an
increase in probability of release of vesicles or (b) an
increase in the available vesicle pool. The vesicle pool was
shown to be unaltered in DLP2 mutants, but the probability
of release, as deduced from paired-pulse facilitation (PPF;
Textbox 2 in “Appendix”), was elevated. Increased numb-
ers of presynaptic active zones with T-bars, specialized
structures involved in vesicle docking and release, were
also observed thus providing a likely structural correlate to
the observed altered synaptic physiology [90]. Postsynaptic
dystrophin may act as a scaffold for signaling molecules
required for the retrograde control of neurotransmitter
release from the presynaptic apparatus. The signaling
pathways involved in the dystrophin-dependent increase in
synaptic vesicle release remain, however, to be elucidated.
In the last decade, it has become clear that both
anterograde, nerve to muscle, and retrograde, muscle to
nerve, signals are required to achieve proper synaptic
homeostasis (reviewed in [104]). Little is known about the
molecular mechanisms required for retrograde control at the
NMJ, but one pathway identified as playing roles in this
process is the bone morphogenetic protein (BMP) pathway
(reviewed in [105]). The secreted BMP pathway member,
glass bottom boat, is believed to mediate a signal emanating
from the muscle by binding to the presynaptic Wishful
Thinking receptor. Interestingly, a genetic interaction was
observed with DLP2 and Wishful Thinking at the NMJ,
suggesting that dystrophin functions in a BMP-dependent
pathway to control homeostatic plasticity [90]. Dystrophin
also interacts with BMP signaling pathways in the
Drosophila wing where their interplay is required for
proper vein formation [106].
What roles do other members of the putative Drosophila
DGC play at the synapse? Thus far, only dystroglycan has
been examined. Intriguingly, the lack of dystroglycan or the
enzyme required for its glycosylation, dPOMT1, both cause
a phenotype that is opposite to the DLP2 dystrophin
phenotype. Loss of postsynaptic dystroglycan or POMT
leads to a decrease in the number of transmitter quanta
released from the presynaptic terminal and a concomitant
decrease in the efficacy of synaptic transmission [102, 103].
The probability of release is decreased in these mutants,
while the number of release sites is not altered. In addition,
while the overall morphology of the NMJ is intact, the ratio
of glutamate receptor subunits is altered in dystroglycan
and POMT mutants because the levels of the DGluRIIB
subunit are reduced.
In Drosophila, the best studied postsynaptic glutamate
receptors are GluRIIA and GluRIIB (reviewed in [107]). The
subunit composition of the postsynaptic glutamate receptors
determines their function and trafficking. Furthermore, the
regulation of glutamate receptor subunit ratios may underlie
aspects of synaptic homeostasis and plasticity. How these
changes would result in alterations in presynaptic release is
not known. Nevertheless, changes in postsynaptic subunit
composition are also important for the maturation of mouse
cholinergic endplates and glutamatergic central synapses
[108].
How might the seemingly differential roles of dystrophin
and dystroglycan at the Drosophila NMJ be explained? The
single mutant analyses have clearly indicated that each of
the two proteins function at the neuromuscular synapse,
but, surprisingly, in distinct and even opposite ways. Since
the phenotypes of dystrophin/dystroglycan double mutant
flies have not yet been reported, the epistatic relationship
between dystroglycan and dystrophin at the NMJ remains
unclear. Dystrophin likely modulates a retrograde signal
that limits transmitter release by, at least in part, inhibiting
the formation of T-bars. Dystroglycan likely acts via a
different mechanism since no alterations in T-bar numbers
were observed in the dystroglycan mutant [103]. It is also
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composition observed in dystroglycan mutants reflects a
direct role of dystroglycan in receptor clustering, as has been
shown for the vertebrate dystroglycan protein in AChR
clustering [109]. Further studies are required in order to
understand these dramatically different roles of dystrophin
and dystroglycan at the NMJ.
The increased synaptic efficacy at the Drosophila DLP2-
deficient NMJ is reminiscent of the elevated levels of
cholinergic neurotransmission observed in C. elegans dys-1
mutants. However, as discussed above, the increased
depolarization observed in mutant worm muscle is most
likely due to the delocalization of the Snf-6 ACh transporter
which results in the inappropriate per durance of ACh in the
synaptic cleft. A similar role of a Drosophila dystrophin-
interacting glutamate transporter at the NMJ cannot be
ruled out.
Roles of the DGC at Central Synapses
We now focus on the roles of dystrophin in the CNS. The
first section describes what has been learned about
dystrophin function in cognitive studies and behavioral
assays which reveal DGC roles in long-term spatial and
nonspatial memory consolidation and emotion, respective-
ly. The following section discusses new mechanistic in-
sights into requirement for dystrophin in receptor clustering
and synaptic plasticity in the mammalian hippocampus
and cerebellum gained, in part, through electrophysiolog-
ical analyses. The subject of the last section is the
recently revealed role of dystrophin in regulating neuro-
transmitter release at a defined cholinergic central syn-
apse in Drosophila.
Reports that describe dystrophins’ involvement in meta-
bolic pathways in the nervous system, such as the altered
glucose metabolism in the brains of DMD patients and mdx
mice, and those that examine the defects in the establishment
of the blood–brain barrier in these mice fall outside the scope
of this review. These subjects are reviewed in [5, 25].
Roles for Dystrophin in Behavior
DMD Is Associated with Mental Retardation
Cognitive impairments occur in approximately one third of
Duchenne patients, highlighting a role for dystrophin in the
nervous system (reviewed in [5, 7, 25]). The average IQ of
boys diagnosed with DMD is 85, while 30% have an IQ
less than 70 (reviewed in [5]). These mental deficits appear
to be nonprogressive and unrelated to the severity of the
muscular dystrophy. Their causes remain unknown. More-
over, morphological abnormalities in the brains of post-
mortem DMD patient are highly variable, ranging from no
abnormalities [110–112] to slight and severe abnormalities,
such as partial cerebral atrophy, neuronal loss and gliosis,
and abnormal arborization and dendritic branching of
cortical pyramidal neurons [111, 113–115].
There are various neuropsychiatric complications asso-
ciated with DMD, such as autism, attention deficit
hyperactivity disorder, obsessive–compulsive disorder, ep-
ilepsy, and febrile convulsion [116]. Mutations in the
human fukutin-related protein gene and POMT1/2 genes,
which affect the glycosylation of α-dystroglycan, also result
in syndromes associated with severe mental retardation
(Fukuyama congenital muscular dystrophy and Walker–
Warburg syndrome), further indicating roles for the DGC in
the development of circuitry required for cognition [26].
Lastly, mutations in ε-sarcoglycan are implicated in
myoclonus–dystonia syndrome, a disease characterized by
dystonia and psychiatric complications, including anxiety
and obsessive–compulsive disorder [117].
The brain-specific DGC(s) consists predominantly of
four components, dystrophin (or utrophin), dystroglycan,
dystrobrevin, and syntrophin (Fig. 1), with variations in the
isoforms present, depending on the specific cell type being
examined. Some neuronal cell types also express the ε- and
ζ-sarcoglycans, but sarcoglycans are more predominantly
expressed in muscle. Dystrophin isoforms are differentially
expressed in subsets of neurons and glia: Dp427 is present
in the cerebral cortex, the limbic system, including the areas
CA1-CA3 of the hippocampus, the basolateral nucleus, and
the lateral nucleus of amygdala, and cerebellar Purkinje
cells [118]. Dp260 is present in the retina [119], Dp140 in
the microvasculature and throughout the brain [120],
Dp116 in Schwann cells of the peripheral nervous system
[121], while Dp71 is highly abundant in most, if not all,
brain areas examined [122]. It is not evident that the lack of
one particular dystrophin isoform is solely responsible for
the neurological disorders associated with DMD, but
mutations in the 3′ end of the gene affecting all isoforms
are most frequently linked to lower IQ scores [123].
Furthermore, most DMD patients, who exhibit neurological
complications, have a genetic deficiency or duplication
distal to exon 44 which most likely alters expression of
Dp140, Dp116, and/or Dp71 [116]. Expression of the
Dp140 isoform, whose promoter and first exon lie in the
large intron between exons 44 and 45 [124], is likely to be
affected by these deletions [125, 126].
Requirements for the DGC in Memory Acquisition
and in Defense and Motor Behavior
Conflicting reports exist concerning possible roles for
dystrophin in learning and memory that have been
established using mouse models. The discrepancies are
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that test distinct learning tasks of dystrophin-deficient mice
[127–129]. In addition, it has become apparent that results
obtained from tests employing the mdx mouse (which only
lacks full-length dystrophin isoform Dp427) likely differ
from those using the mdx
3cv mouse (which lacks all
dystrophin isoforms). Together, the results suggest that the
full-length isoform is essential for the function of dystro-
phin in cognition and memory involving hippocampal and
forebrain function (reviewed in [25]). The specific roles for
the smaller isoforms in cognition are not yet clearly
defined. Since mdx mice do not exhibit any significant
signs of muscular dystrophy during the first 6 months of
postnatal life, possibly due to sufficient regeneration of
muscle, behavior of mdx mice can be studied in the absence
of extensive muscle degeneration.
Recently, Vaillend and colleagues addressed memory
impairment in mdx mice using spatially and nonspatially
defined tasks that can be rapidly learned [130]. The use of
these behavioral paradigms reduces the possibility that
extended training procedures would inadvertently improve
memory function and mask memory deficits [131, 132].
The tests were based on (1) object recognition and (2)
spatial learning in a water maze. Naturally occurring
novelty-seeking behavior was not altered in the mdx mouse
confronted with new objects. Both mdx and control mice
spent longer times exploring a novel object when it was
copresented with a familiar object to which they had been
exposed 10 min prior. However, when the time between
exposure and the test was prolonged to 24 h, the mdx group
would explore both objects equally, whereas the control
group would still prefer a novel object. This observation is
consistent with the mdx mice exhibiting long-term recog-
nition memory impairments. Similar results were obtained
when mice were trained to find a submerged platform in a
water bath. Mice of the control group would still be able to
efficiently locate the platform 24 h after training, as
measured by the time spent in the target area, whereas the
mdx mice would not show a preference for the area where
the platform was located. Thus, apparently, consolidation or
expression of long-term memory is impaired in mdx mice
[130].
The lack of the large dystrophin isoforms in mdx mice
also impacts on emotional behavior and fear memory,
which reflects amygdala transmission. Mdx mice have an
increased defensive freezing response to restraint compared
to control mice [133]. This behavior can be partially rescued
by oligonucleotide-mediated exon skipping that facilitates
expression of a truncated dystrophin in the brain, not in the
muscle [133]. These data support the hypothesis that
dystrophin is required for wild-type emotional behavior.
Behavioral tests have also been performed on double
knockout α-a n dβ-dystrobrevin mice [134]. These mice
exhibit abnormal sensorimotor behaviors that reflect cerebellar
dysfunction, while the single dystrobrevin knockout mice
apparently behave normally.
In the next two sections, electrophysiological studies that
examine the roles of the different DGC members at
mammalian central synapses are discussed. Furthermore,
studies are reviewed that indicate that a number of the DGC
members (dystrophin, dystrobrevin, syntrophin, and dystro-
glycan) are present at the postsynaptic side of mammalian
inhibitory GABAergic synapses in the hippocampus and in
cerebellar Purkinje cells [135], where they are required for
synapse function and plasticity. Lack of expression of
dystrophin at these sites might contribute to the behavioral
defects observed in mdx mice and the mental retardation
displayed by DMD patients.
Dystrophin Function in Receptor Clustering and Synaptic
Plasticity of Mammalian Hippocampal and Cerebellar
GABAergic Synapses
In the mammalian brain, full-length dystrophin, Dp427 is
expressed at the postsynaptic membranes of hippocampal
pyramidal neurons, neocortical pyramidal neurons [136],
amygdala, and cerebellar Purkinje cells [133] where it
colocalizes with inhibitory GABAA receptor clusters [133,
137]. No gross changes in morphology or increased
apoptosis were apparent in the mdx mouse hippocampal
CA1 area [138]. However, in other areas of the mdx brain,
for example in the spinal trigeminal nucleus, the number of
neurons is almost 50% decreased compared to wild-type
mice [139]. Interestingly, in these same mice, α1- and α2-
GABAA clusters are significantly reduced in number [133,
137, 140]. Dystrophin colocalizes with other DGC proteins
such as dystrobrevin, the syntrophins, and β-dystroglycan
to inhibitory GABAergic synapses [25, 141]. Furthermore,
in dystroglycan conditional knockout mice, these synapses no
longer contain dystrophin [142]. α-a n dβ-Dystrobrevin
double knockout mice have lost dystrophin, and mdx mice
have lost dystrobrevin localization from the cerebellar
GABAA clusters [134] and exhibit a decrease in the size
and numbers of α1 subunit GABAA receptor clusters.
Together, these data suggest that the DGC proteins are, at
least partially, interdependent for their targeting to GABAer-
gic synapses and that the DGC likely stabilizes GABAA
receptor clusters at these synapses.
There is ample evidence that the DGC members also
modulatesynapse function atinhibitoryGABAergic synapses
in the cerebellum [140], the amygdala [133], and the
hippocampus (reviewed in [25]). In the mdx cerebellar
Purkinje cells, there are significant reductions in both the
frequency and amplitude of spontaneous inhibitory postsyn-
aptic currents (mIPSP; Textbox 2 in “Appendix”), consistent
with the reduction in the number and size of GABAA
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in inhibitory input in these cells was also recorded when
GABAergic signaling was blocked resulting in a smaller
increase in the amplitude of evoked postsynaptic potentials
(EPSPs; Textbox 2 in “Appendix”), compared to wild-type
controls [143]. Furthermore, decreased long-term depression
(LTD; Textbox 2 in “Appendix”) was observed in mdx
Purkinje cells, which possibly leads to a disruption of
cerebellar long-term plasticity [144]. These results may, at
least in part, explain some of the behavioral problems and
cognitive impairments reported in mdx mice and DMD
patients [140].
In the hippocampus, loss of Dp427 in mdx mice does not
affect inhibitory postsynaptic currents (IPSCs; Textbox 2 in
“Appendix”) evoked in the pyramidal cell layer [145].
However, a lack of facilitation was shown by PPF analysis,
which suggests that the probability of inhibitory synaptic
release is higher in mdx mice compared to control mice at
this particular synapse. This effect correlates with an
observed increased mIPSC frequency, contrary to what is
observed at the cerebellar Purkinje cell synapses discussed
above [145]. Several studies by Vaillend and colleagues
[129, 130, 146] demonstrated, again in mdx mice, an
increase in neuronal facilitation, a sustained effect leading
to enhancement of the maintenance phase of hippocampal
long-term potentiation (LTP; Textbox 2 in “Appendix”), as
well as an enhancement of short-term potentiation (STP;
Textbox 2 in “Appendix”) and depression (Textbox 2 in
“Appendix”). The enhanced STP and STD were prevented
when the GABAA receptor antagonist, bicuculline, was
applied [130, 146]. Collectively, these data point toward the
dystrophin Dp427 deficiency being associated with a
sustained increase in synaptic efficacy and excitability of
CA1 hippocampal neurons. Moreover, dystroglycan condi-
tional knockout mice that lack dystroglycan in brain also
exhibit deficits in hippocampal LTP [147].
The above-mentioned studies, while showing different
electrical responses to dystrophin deficiency in the cerebellum
versusthehippocampus,suggestthatthealterationofinhibitory
synaptic transmission may contribute to memory deficits
evident in mdx mice. Similar memory impairments correlating
with enhanced synaptic efficacy and LTP have been observed
in other mouse models, including a model for Alzheimer’s
disease, and mice with disrupted genes encoding PSD-95 or a
subunit of the ionotropic glutamate receptor [148–151].
Finally, the effects of the loss of the Dp71 isoform on
mouse brain function employing electrophysiology and
behavioral studies were recently reported [152]. Interesting-
ly, glutamatergic transmission is enhanced and synaptic
plasticity reduced in Dp71-deficient CA1 hippocampal
neurons. Furthermore, Dp71 knockout mice display reduced
exploratory and novelty seeking behavior, mild retention
deficits in inhibitory avoidance, and impairments in spatial
learning and memory acquisition [152]. Together, the studies
described above highlight the different roles that distinct
dystrophin isoforms play at central synapses.
Drosophila Dystrophin Modulates Neurotransmitter
Release of Cholinergic Central Synapses
Similarly to its mammalian counterpart, the Drosophila
dystrophin gene also encodes several short isoforms. One of
these, Dp186, is expressed predominantly, if not exclusive-
ly, in the CNS [32]. Dp186 has been localized, in particular,
to cholinergic synapses between interneurons and moto-
neurons. Whole-cell voltage clamp recordings from identi-
fied motoneurons, in the larval CNS, show that excitatory
synaptic currents are significantly increased in the absence
of Dp186 compared to those measured in controls [153].
Recordings were also performed in the presence of
tetrodotoxin, which blocks evoked transmitter release,
allowing measurement of only spontaneous miniature
synaptic currents. The amplitudes of these miniature
synaptic currents were not altered in the mutants, indicating
that the postsynaptic AChR field was not affected by the
absence of Dp186. However, although amplitude was
normal, the frequency of the miniature synaptic currents
was significantly increased in the mutants compared to wild
types. Together, these data indicate that lack of Dp186 in
the CNS results in an increased probability of presynaptic
(ACh) neurotransmitter release. This mutant phenotype
could be fully rescued only when a wild-type Dp186
transgene was expressed postsynaptically, but not presyn-
aptically, demonstrating that Dp186 exerts a role consistent
with retrograde signaling at interneuronal CNS synapses.
Based on similarity of effect, this role likely is similar to
that of the large Drosophila DLP2 isoform at the NMJ [90].
Roles of the DGC in the Retina
One of the earliest described nervous system-related clinical
features of DMD patients affects the visual system [154,
155]. While DMD patients have generally normal vision,
they do exhibit altered responses to certain light/dark
stimuli as measured by electroretinography. Here, recent
findings are reviewed that shed light onto DGC function at
retinal synapses gained from the use of electrophysiological
approaches in animal models.
The DGC Is Required for Correct Electrical Activity
and Formation of the Mammalian Retina
Several dystrophin isoforms are differentially expressed in
the murine retina [6, 156]. Based on a number of studies, in
which different dystrophin isoforms have been localized to
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isoform likely contributes a unique function [157]. For
example, Dp427 and Dp260 are located in the outer
plexiform layer (OPL), where photoreceptors form synapses
with horizontal and bipolar cells. Dp71 is detected in the
inner limiting membrane, the Müller glia, and the perivas-
cular astrocytes, while Dp140 is also present at perivascular
astrocytes [158, 159]. A special type of synapse at the OPL,
called the ribbon synapse, connects axons of photoreceptor
cells to bipolar cell dendrites. Visual information is trans-
mitted from the photoreceptor cell to the ganglia cell via the
bipolar cells. At the ribbon synapse, Dp260, Dp140, and
Dp71, as well as β-dystroglycan, are expressed presynapti-
cally, in contrast to the postsynaptic expression of DGC
members in other parts of the brain and NMJ [51, 160–163].
As indicated above, general eye exams of DMD patients
indicate normal visual abilities and no gross abnormalities
nor evidence of night blindness. However, DMD patients
present with abnormal electroretinograms (ERG; [155];
Textbox 3 in “Appendix”). When measured in a dark-
adapted (scotopic) retina, the ERG shows a reduced
amplitude of the b-wave response in the majority of DMD
patients. Further analyses of these ERG waveforms suggest
that aberrant dystrophin expression impairs synaptic trans-
mission specifically between the rod and cone photorecep-
tor cells and their postsynaptic targets, the bipolar ON cells
in the OPL [164]. Consistent with these findings, dystro-
phin expression is observed at these synapses.
Although mdx mice, lacking Dp427, display normal
ERG [154], mdx
CV3 mice, lacking all dystrophin isoforms,
show a decreased b-wave response [165]. Mice that only
lack Dp71 [166] have normal ERGs with no significant
changes of the b-wave amplitude and kinetics [167]. Based
on these results and the above-mentioned expression
analyses, the Dp260 isoform is thought to be the isoform
likely required for proper b-wave formation and timing.
Collaborating evidence for this hypothesis has been
obtained from clinical studies of DMD patients. A subset
of DMD patients with deletions downstream of exon 30,
affecting the splicing and transcription of Dp260, exhibit a
red–green color vision defect, while DMD patients, who
have dystrophin mutations upstream of exon 30 (solely
affecting Dp427) have seemingly normal color vision.
Thus, this color vision defect may be caused by a loss of
the dystrophin isoform Dp260 [159, 168].
Little is known about the involvement of other DGC
members in retinal function. While β-dystrobrevin coloc-
alizes with dystrophin and β-dystroglycan at photoreceptor
cell termini in the OPL, dystrobrevin null mutant mice
display normal ERGs [134]. The localization of dystrophin
in the retina is, moreover, not dependent on dystrobrevin
expression, unlike their interdependence at inhibitory
cellebellar Purkinje synapses. Interestingly, a novel dystro-
glycan ligand, called pikachurin, has been recently identi-
fied which presynaptically colocalizes with dystrophin and
dystroglycan at the photoreceptor ribbon synapse [169].
Pikachurin null mice have improper apposition of bipolar
dendritic tips to the photoreceptor ribbon synapse, leading
to prolonged retinal synaptic transmission from photo-
receptors to bipolars. Pikachurin is therefore important for
both the development and function of the ribbon synapse;
synapses are formed in Pikachurin null mutants, but the
subsequent invagination of the photoreceptor axon sur-
rounding the dendrites of bipolar cells is abnormal,
affecting the physiology of visual perception [169]. These
animal studies might further our understanding of the exact
nature of the defects in vision of DMD patients.
Drosophila DGC Is Required for Axon Guidance
of Photoreceptor Neurons
Studies of the Drosophila optic system recently demon-
strated that dystroglycan and dystrophin are required during
axon pathfinding of both photoreceptor neurons and their
supporting glial cells present in the lamina plexus of the
larval brain [21]. Lack of either dystroglycan or dystrophin
results in similarly aberrant axon projection patterns:
clumping photoreceptor axons at the lamina that are
irregularly distributed at the termination zone of the lamina
plexus. These abnormalities were also observed when
expression of dystroglycan or different isoforms of dystro-
phin (all isoforms, DLP1-3, or the smaller isoforms only)
were reduced by RNA interference either in the photore-
ceptor axons or the glia, suggesting that both cell types are
required for wild-type axon patterning. The observed axon
pathfinding phenotypes are reminiscent of phenotypes
observed in flies deficient for genes encoding the adaptor
protein dock [170] and the insulin receptor (InR) [171].
Genetic interaction studies showed that dystroglycan indeed
strongly interacts with dock and InR, whereas dystrophin
does not. From these observations, a model was proposed
in which dystroglycan may selectively interact with either
dystrophin or InR and dock, thereby modulating the cyto-
skeletal rearrangements in the photoreceptor neurons re-
quired for appropriate axonal projections in the retina [21].
Concluding Remarks and Future Perspectives
Major advances have been made in the clinical assessment
of the cognitive and neuropsychiatric impairments of DMD
patients and toward the development of animal models to
investigate DGC function. However, despite these advances,
our understanding of the roles of the complex remains
incomplete. A primary challenge ahead for elucidating DGC
function in the nervous system is to comprehend how the
14 Mol Neurobiol (2010) 41:1–21absence of the complex leads to the observed defects in
synaptic plasticity, behavioral abnormalities, and visual
impairments. At the mechanistic level, it is clear that both
at the NMJ and at central synapses, the DGC is required for
clustering of major neurotransmitter receptors, such as the
AChRs at the NMJ and inhibitory GABAA receptor clusters
in the hippocampus, the cerebellum, and the amygdala. For a
number of these synapses, it has been established that the
absence of dystrophin results in aberrant synapse maturation
and neurotransmission. Interestingly, DGC/UGC function is
apparently not neurotransmitter specific, since the complex is
required for appropriate regulation of glutamatergic
(Drosophila NMJ and mammalian brain), GABAergic
(mammalian brain), and cholinergic (the mammalian and C.
elegans NMJ and the Drosophila central synapse) transmis-
sion. Furthermore, it functions at inhibitory (GABAergic)
and excitatory (glutamatergic and cholinergic) synapses.
The definition of the precise synaptic roles of the DGC is
complicated by the findings that the effects of DGC
deficiency clearly differ depending on the particular
synapse studied. In the DGC mutant hippocampus, no
gross structural changes in neuronal fate or axon outgrowth
were observed. Clear abnormalities in synaptic plasticity
and LTP, correlating with alterations in receptor clustering
and enhanced synaptic transmission, were, however, evi-
dent. In mdx cerebellar Purkinje cells, a reduction in the
number of postsynaptically localized GABAA clusters has
been associated with a decreased amplitude and frequency
of spontaneous inhibitory postsynaptic currents and reduc-
tion in LTD. These defects may underlie the cognitive
impairments these mice exhibit in learning and memory
behavioral paradigms. In the coming years, it will hopefully
be feasible to directly correlate the mechanistic defects in
mdx mice GABAA receptor function in the hippocampus
and the cerebellum with the observed abnormalities in
synaptic plasticity and behavior.
While studies on DGC function in the brain and at the
NMJ point toward a mainly postsynaptic role, the complex
accumulates at the presynaptic side of the ribbon synapse in
the visual system. Here, it is required not only for correct
(light-induced) synaptic transmission but also for the
structural development of this synapse. In contrast, a role
in the stabilization and maturation of the postsynaptically
localized neurotransmitter receptor clusters and synaptic
folds is evident at the mammalian NMJ, but early
morphological development of the NMJ seems to be
unaffected in DGC mutants.
Invertebrate organisms, particularly the worm and the
fruit fly, have also proven useful for investigating DGC
function at the synapse. The fruit fly larval NMJ and
central synapses are highly amenable to electrophysio-
logical analysis and specific roles for individual dystro-
phin isoforms have been identified. Thus, it has been
shown that the large dystrophin isoform DLP2 at the
glutamatergic NMJ and the smaller Dp186 isoform at
cholinergic central synapses, both postsynaptically local-
ized, are required for wild-type levels of presynaptic
neurotransmitter release. At the NMJ, at least, this
function likely requires BMP signal transduction. Future
studies using these invertebrate models, where electro-
physiology can be combined with genetic manipulation
of single identified cells, should continue to reveal the
molecules with which dystrophin interacts at the synapse.
Invertebrate animals might also be employed for the
large scale screening of potentially therapeutically useful
compounds that target DGC function.
Mammalian dystrophin isoforms may also play roles in
the regulation of presynaptic neurotransmitter release as has
been observed in Drosophila. First, the lack of the Dp71
isoform in the mouse hippocampus leads to alterations in
PPF suggesting an increase in presynaptic glutamate
release. Secondly, increased mIPSC frequency and reduced
PPF of the eIPSCs are observed in the Dp427-deficient
hippocampus also indicating increased probability of
release. However, the mechanisms underlying these effects
on transmitter release remain unknown.
While Drosophila models of dystrophin dysfunction are
being increasingly employed, it is currently difficult to
precisely determine which of the various fly and mamma-
lian isoforms are functional orthologs. This is for two main
reasons: (1) the primary amino acid sequences of the
isoform-specific amino-termini differ significantly between
Drosophila and mammals (Textbox 1 in “Appendix”) and
there are no conserved motifs evident and (b) mutants of
many of the small isoforms in both species have yet to be
examined; thus, their functions are unknown. It remains
possible, however, that apparently divergent dystrophin
amino-termini play analogous roles in different species.
Even if certain aspects of dystrophin function prove,
however, to be different between species, studying its roles
at various types of synapses in multiple species should help
to reveal the biological strategies that have evolved to wire
a complex nervous system. This information will aid in the
development of novel therapeutic interventions for neuro-
logical disorders.
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Textbox 1: Dystrophin Isoforms in Mammals, Drosophila,
and Worms and Their Mutants
Mammals
The human/mouse DMD gene has seven promoters driving
the expression of mRNAs encoding the isoforms, Dp427
(B), Dp427 (M), Dp427 (P), Dp260, Dp140, Dp116, and
Dp71. Three promoters drive expression of the brain- (B),
muscle- (M), and Purkinje cell (P)-specific large Dp427
isoforms which differ in their 5′ untranslated and first
codon exons which are spliced to a common exon 2. All
three large isoforms bear an actin-binding domain, four
hinge domains interrupted by 24 spectrin-like repeats that
form triple-helical coiled-coils (CC) and a C-terminal
region that contains domains involved in protein–protein
interactions, including a WW domain, a ZZ domain within
a cysteine-rich region and a CC domain near the carboxy-
terminus. The smaller isoforms have the common carboxy-
terminal region, no apparent actin-binding domains, and a
variable number of spectrin-like repeats (Dp260 has 15,
Dp140 has 5, Dp116 has 2, and Dp71 has none). Unlike
Drosophila and C. elegans, mammals also have an utrophin
gene whose encoded protein is highly similar to dystrophin
with respect to sequence and domain structure, particularly
in the carboxy-terminal domain.
Drosophila
Drosophila’s dystrophin gene contains six identified pro-
moters driving the expression of the following isoforms:
DLP1, DLP2, DLP3, Dp186, Dp205, and Dp117. Similar to
the large mammalian isoforms, Drosophila DLP1, 2, 3
differ only in their untranslated and first coding exons, but
all contain the other conserved protein domain domains
described for the mammalian Dp427 isoforms, including 22
spectrin-like repeats [101]. The smaller fly isoforms do not
contain conserved actin-binding domains, but Dp186,
Dp205, and Dp117 contain unique amino-terminal domains
conserved with other Drosophila species and the carboxy-
terminal domains including WW, ZZ, and CC domains that
are present in the mammalian dystrophin protein isoforms.
Dp186, Dp205, and Dp117 contain 4, 2 and no spectrin-like
repeats, respectively [101].
C. elegans
C. elegans’ dystrophin gene, dys1, encodes a single large
isoform which bears an actin-binding domain, seven
spectrin-like repeats, and the conserved carboxy-terminal
domain containing the WW, ZZ, and CC domains.
Dystrophin Isoforms Affected in Human DMD Patients
and Model Organisms
Approximately two thirds of all DMD patients have large
deletions in the dystrophin gene, mostly located at two hot
spots that result in the truncation of all protein isoforms and
the loss of their common C-terminal domains. The
remainder of DMD patients has small deletions or point
mutations that introduce stop codons and other mutations
that lead to (partial or full) loss of dystrophin protein
isoform production or decreased protein stability. Mouse
studies discussed in this review employ three different
dystrophin-deficient mouse strains, mdx (lacking only the
large Dp427 isoforms), mdx
3Cv (lacking all isoforms), and
Dp71-specific knockout mice. An additional mouse model,
mdx
52, lacking the Dp427, Dp260, and Dp140 isoforms has
been generated, but no nervous system phenotypes have
been reported. The various mammalian models of DMD
have been recently reviewed [172].
The Drosophila mutants described here include mutants
lacking only the large DLP2 or CNS-specific Dp186
isoforms or with Dp117 or all dystrophin isoform expres-
sion levels reduced by transgenic RNA interference. The C.
elegans dys1 mutant lacks the sole dystrophin isoform.
Dystrophin isoform expression domains are presented in
Table 2.
Textbox 2: Electrophysiological Terminology
EPSP is a transient depolarization of the postsynaptic
membrane caused by the flow of positively charged ions
(usually Na
+) into the postsynaptic cell as a result of the
opening of ligand-gated channels. Depolarization increases
the chance of the occurrence of an action potential as the
membrane is pushed toward a threshold for the opening of
voltage-gated cation channels (Na
+ and/or Ca
2+). In
contrast, IPSPs (or IPSCs) are mediated by ligand-gated
anion channels (Cl
−) and their activation hyperpolarizes the
membrane, decreasing the chance of firing action poten-
tials. The spontaneous release of single neurotransmitter
quanta from the presynaptic excitatory neuron generates
mEPSPs, while the mIPSPs (or mIPSCs) are generated by
the release of single quanta at inhibitory synapses [173].
PPF can be described as a short-term form of synaptic
plasticity. PPF is the short-lasting (<1 s) increase in
postsynaptic potential evoked by a second impulse. It
results in an increase in the probability of transmitter
release by residual Ca
2+ only when the probability of
synaptic vesicle release is low [174].
Another physiological feature in the hippocampus is
LTP, first described by Bliss and Lomo [175]. LTP has been
defined as a long-lasting increase in synaptic efficacy,
meaning that a presynaptic neuron gains an increased
16 Mol Neurobiol (2010) 41:1–21ability to fire an action potential as a result of brief high-
frequency stimulation. LTP can be induced in three major
interconnected synaptic circuits of the hippocampus from
the dentate gyrus via the CA3 to the CA1 pyramidal
neurons. LTP is measured as the percentage increase in the
slope of the EPSP relative to the baseline EPSP slope
before high-frequency stimulation. LTD is the opposite
process, a decrease in neuronal synapse efficacy which can
be long lasting, from an hour to days. It is thought to result
from changes in postsynaptic receptor density, although
changes in presynaptic release may also play a role. LTD is
involved in learning and memory processing mediated by
the hippocampus and may be important for the clearing of
old memory traces [176]. In the cerebellum, LTD has been
hypothesized to be important for motor learning. The
changes in synaptic strength may be either transient (short
term) or persistent (long term). STP refers to synaptic
enhancement that can be induced rapidly but maintained
only for up to 20 min [177], while STD results from an
activity-dependent reduction in neurotransmitter release
[178].
Textbox 3: Electroretinography
Electroretinography is used to measure the activity of
groups of retinal neurons in response to light stimulation,
including the photoreceptors (rods and cones) and the
ganglion cells. Essentially, the technique records the
alterations in the extracellular ion concentration surround-
ing neurons that changes during action potential firing. If
the ERG is performed on a dark-adapted eye (scotopic), it
reflects the rod system, and the ERG performed on a light-
adapted eye (photopic) shows the response for the cone
system. There are two ERG waves: a-waves which are
initial negative waves, followed by positive b-waves. The
a-wave and b-wave are responsible for a hyperpolarization
of rod cells and the summation of the depolarization of ON-
bipolar cells, respectively. There are two types of bipolar
cells, ON (depolarizing)-bipolar cells which activate the
ganglion cells in response to an increased brightness, or
OFF (hyperpolarizing)-bipolar cells that activate after
decreased brightness [179].
References
1. Blake DJ et al (2002) Function and genetics of dystrophin and
dystrophin-related proteins in muscle. Physiol Rev 82:291–329
2. Duchenne G (1868) Recherches sur la paralysie musculaire
pseudohypertrophique, ou paralysie myosclerosique. Arch Gen
Med 11:5–25
3. Hoffman EP et al (1987) Dystrophin: the protein product of the
Duchenne muscular dystrophy locus. Cell 51:919–928
4. Koenig M et al (1987) Complete cloning of the Duchenne
muscular dystrophy (DMD) cDNA and preliminary genomic
organization of the DMD gene in normal and affected individ-
uals. Cell 50:509–517
5. Anderson JL et al (2002) Brain function in Duchenne muscular
dystrophy. Brain 125:4–13
6. Muntoni F et al (2003) Dystrophin and mutations: one gene,
several proteins, multiple phenotypes. Lancet Neurol 2:731–740
7. Blake DJ, Kröger S (2000) The neurobiology of Duchenne
muscular dystrophy: learning lessons from muscle? Trends
Neurosci 23:92–99
8. Love DR et al (1993) Dystrophin and dystrophin-related proteins:
a review of protein and RNA studies. Neuromuscul Disord 3:5–21
9. Roberts RG et al (1996) Characterization of DRP2, a novel
human dystrophin homologue. Nat Genet 13:223–226
10. Haenggi T, Fritschy JM (2006) Role of dystrophin and utrophin
for assembly and function of the dystrophin glycoprotein
complex in non-muscle tissue. Cell Mol Life Sci 63:1614–1631
11. Weir AP et al (2002) A- and B-utrophin have different
expression patterns and are differentially up-regulated in mdx
muscle. J Biol Chem 277:45285–45290
12. Allikian M, EM EM (2007) Processing and assembly of the
dystrophin glycoprotein complex. Traffic 8:177–183
13. Ervasti JM, Campbell KP (1991) Membrane organization of the
dystrophin-glycoprotein complex. Cell 66:1121–1131
14. Blake DJ et al (1999) Different dystrophin-like complexes are
expressed in neurons and glia. J. Cell Biol. 147:645–658
15. Blank M et al (1999) Dystrophin and beta-dystroglycan in
photoreceptor terminals from normal and mdx3Cv mouse
retinae. Eur J NeuroSci 11:2121–2133
16. Blank M et al (1997) Subcellular concentration of beta-
dystroglycan in photoreceptors and glial cells of the chick retina.
J Comp Neurol 389:668–678
17. Ervasti JM, Campbell KP (1993) A role for the dystrophin–
glycoprotein complex as a transmembrane linker between
laminin and actin. J Cell Biol 122:809–823
18. Rando TA (2001) The dystrophin–glycoprotein complex, cellular
signaling, and the regulation of cell survival in the muscular
dystrophies. Muscle Nerve 24:1575–1594
19. Spence HJ et al (2004) Dystroglycan, a scaffold for the ERK–
MAP kinase cascade. EMBO Rep 5:484–489
20. Hashimoto R, Yamaguchi M (2006) Genetic link between β-
sarcoglycan and the Egfr signaling pathway. Biochem Biophys
Res Commun 348:212–221
21. Shcherbata HR et al (2007) Dissecting muscle and neuronal
disorders in a Drosophila model of muscular dystrophy. EMBO J
26:481–493
22. Carlson CG (1998) The dystrophinopathies: an alternative to the
structural hypothesis. Neurobiol Dis 5:3–15
23. Gillis JM (1996) Membrane abnormalities and Ca homeostasis in
muscles of the mdx mouse, an animal model of the Duchenne
muscular dystrophy: a review. Acta Physiol Scand 156:397–406
24. Srour M et al (2008) An instructive case of an 8-year-old boy
with intellectual disability. Semin Pediatr Neurol 15:154–155
25. Waite A et al (2009) The neurobiology of the dystrophin-
associated glycoprotein complex. Ann Med 41:344–359
26. Barresi R, Campbell KP (2006) Dystroglycan: from biosynthesis
to pathogenesis of human disease. J Cell Sci 119:199–207
27. Balci B et al (2005) An autosomal recessive limb girdle muscular
dystrophy (LGMD2) with mild mental retardation is allelic to
Walker–Warburg syndrome (WWS) caused by a mutation in the
POMT1 gene. Neuromuscul Disord 15:271–275
28. Beltrán-Valero de Bernabé D et al (2002) Mutations in the O-
mannosyltransferase gene POMT1 give rise to the severe
neuronal migration disorder Walker–Warburg syndrome. Am J
Hum Genet 71:1033–1043
Mol Neurobiol (2010) 41:1–21 1729. van Ommen GJ et al (2008) The therapeutic potential of
antisense-mediated exon skipping. Curr Opin Mol Ther
10:140–149
30. van Deutekom JC et al (2007) Local dystrophin restoration with
antisense oligonucleotide PRO051. N Engl J Med 357:2677–
2686
31. Greener MJ, Roberts RG (2000) Conservation of components of
the dystrophin complex in Drosophila. FEBS Lett 482:13–18
32. Dekkers LC et al (2004) Embryonic expression patterns of the
Drosophila dystrophin-associated glycoprotein complex ortho-
logs. Gene Expr Patterns 4:153–159
33. Grisoni K et al (2002) Genetic evidence for a dystrophin-
glycoprotein complex (DGC) in Caenorhabditis elegans. Gene
294:77–86
34. Allikian MJ et al (2007) Reduced life span with heart and muscle
dysfunction in Drosophila sarcoglycan mutants. Hum Mol Genet
16:2933–2943
35. Haines N et al (2007) Dystroglycan and protein O-
mannosyltransferases 1 and 2 are required to maintain integrity
of Drosophila larval muscles. Mol Biol Cell 18:4721–4730
36. Taghli-Lamallem O et al (2008) Dystrophin deficiency in
Drosophila reduces lifespan and causes a dilated cardiomyopathy
phenotype. Aging Cell 7:237–249
37. van der Plas MC et al (2007) Drosophila dystrophin is required
for integrity of the musculature. Mech Dev 124:617–630
38. Gieseler K et al (2000) Genetic suppression of phenotypes
arising from mutations in dystrophin-related genes in Caeno-
rhabditis elegans. Curr Biol 10:1092–1097
39. Ozawa E et al (2005) Molecular and cell biology of the
sarcoglycan complex. Muscle Nerve 32:563–576
40. Rafael JA et al (2000) Dystrophin and utrophin influence fiber
type composition and post-synaptic membrane structure. Hum
Mol Genet 9:1357–1367
41. Wood SJ, Slater CR (1998) Beta-spectrin is colocalized with
both voltage-gated sodium channels and ankyrinG at the adult rat
neuromuscular junction. J Cell Biol 140:675–684
42. Bewick GS et al (1996) Spatial relationships of utrophin,
dystrophin, beta-dystroglycan and beta-spectrin to acetylcholine
receptor clusters during postnatal maturation of the rat neuro-
muscular junction. J Neurocytol 25:367–379
43. Marchand S, Cartaud FS-MJ (2001) Differential targeting of
components of the dystrophin complex to the postsynaptic
membrane. Eur J NeuroSci 13:221–229
44. Ayalon G et al (2008) An ankyrin-based mechanism for
functional organization of dystrophin and dystroglycan. Cell
135:1189–1200
45. Burden SJ (2002) Building the vertebrate neuromuscular
synapse. J Neurobiol 53:501–511
46. Sanes JR, Lichtman JW (1999) Development of the vertebrate
neuromuscular junction. Ann Rev Neurosci 22:389–442
47. Sanes JR, Lichtman JW (2001) Induction, assembly, maturation
and maintenance of a postsynaptic apparatus. Nature Rev
Neurosci 2:791–805
48. Kim N et al (2008) Lrp4 is a receptor for Agrin and forms a
complex with MuSK. Cell 135:334–342
49. Zhang B et al (2008) LRP4 serves as a coreceptor of agrin.
Neuron 60:285–297
50. Linnoila J et al (2008) A mammalian homolog of Drosophila
tumorous imaginal discs, Tid1, mediates agrin signaling at the
neuromuscular junction. Neuron 60:625–641
51. Banks GB et al (2003) The postsynaptic submembrane machinery
at the neuromuscular junction: requirement for rapsyn and the
utrophin/dystrophin-associated complex. J Neurocytol 32:709–726
52. Adams ME et al (2000) Absence of alpha-syntrophin leads to
structurally aberrant neuromuscular synapses deficient in utro-
phin. J Cell Biol 150:1385–1398
53. Akaaboune M et al (2002) Neurotransmitter receptor dynamics
studied in vivo by reversible photo-unbinding of fluorescent
ligands. Neuron 34:865–876
54. Deconinck AE et al (1997) Postsynaptic abnormalities at the
neuromuscular junctions of utrophin-deficient mice. J Cell Biol
136:883–894
55. Grady RM et al (1997) Subtle neuromuscular defects in
utrophin-deficient mice. J Cell Biol 136:871–882
56. Jacobson C et al (2001) The dystroglycan complex is necessary
for stabilization of acetylcholine receptor clusters at neuromus-
cular junctions and formation of the synaptic basement mem-
brane. J Cell Biol 152:435–450
57. Deconinck AE et al (1997) Utrophin–dystrophin-deficient mice
as a model for Duchenne muscular dystrophy. Cell 90:717–727
58. Grady RM et al (1997) Skeletal and cardiac myopathies in mice
lacking utrophin and dystrophin: a model for Duchenne muscular
dystrophy. Cell 90:729–738
59. Grady RM et al (1999) Role for alpha-dystrobrevin in the
pathogenesis of dystrophin-dependent muscular dystrophies.
Nature Cell Biol 1:215–220
60. Grady RM et al (2000) Maturation and maintenance of the
neuromuscular synapse: genetic evidence for roles of the
dystrophin–glycoprotein complex. Neuron 25:279–293
61. Carlson CG, Roshek DM (2001) Adult dystrophic (mdx)
endplates exhibit reduced quantal size and enhanced quantal
variation. Pflugers Arch 442:369–375
62. Nagel A et al (1990) Neuromuscular transmission in the mdx
mouse. Muscle Nerve 13:742–749
63. Grady RM et al (2003) Tyrosine-phosphorylated and non-
phosphorylated isoforms of alpha-dystrobrevin: roles in skeletal
muscle and its neuromuscular and myotendinous junctions. J
Cell Biol 160:741–752
64. Ceccarini M et al (2007) Association of dystrobrevin and
regulatory subunit of protein kinase A: a new role for
dystrobrevin as a scaffold for signaling proteins. J Mol Biol
371:1174–1187
65. Waltereit R, Weller M (2003) Signaling from cAMP/PKA to
MAPK and synaptic plasticity. Mol Neurobiol 27:99–106
66. Southan GJ, Szabó C (1996) Selective pharmacological inhibi-
tion of distinct nitric oxide synthase isoforms. Biochem
Pharmacol 51:383–394
67. Gücüyener K et al (2000) The serum nitric oxide levels in
patients with Duchenne muscular dystrophy. Brain Dev 22:181–
183
68. Feil R, Kleppisch T (2008) NO/cGMP-dependent modulation of
synaptic transmission. Handb Exp Pharmacol 184:529–560
69. Chaubourt E et al (2002) Muscular nitric oxide synthase
(muNOS) and utrophin. J Physiol-Paris 96:43–52
70. Daniel S, Chao FS (1998) Muscular dystrophy in mdx mice
despite lack of neuronal nitric oxide synthase. J Neurochem
71:784–789
71. Shiao T et al (2004) Defects in neuromuscular junction structure
in dystrophic muscle are corrected by expression of a NOS
transgene in dystrophin-deficient muscles, but not in muscles
lacking α and β -syntrophins. Hum Mol Genet 13:1873–1884
72. Lai Y et al (2009) Dystrophins carrying spectrin-like repeats 16
and 17 anchor nNOS to the sarcolemma and enhance exercise
performance in a mouse model of muscular dystrophy. J Clin
Invest 119:624–635
73. Bellamy TC et al (2002) On the activation of soluble guanylyl
cyclase by nitric oxide. PNAS (USA) 99:507–510
74. Bergandi L et al (2003) Insulin stimulates glucose transport via
nitric oxide/cyclic GMP pathway in human vascular smooth
muscle cells. Arterioscler Thromb Vasc Biol 23:2215–2221
75. Christensen EN, Mendelsohn ME (2006) Cyclic GMP-dependent
protein kinase I{alpha} inhibits thrombin receptor-mediated
18 Mol Neurobiol (2010) 41:1–21calcium mobilization in vascular smooth muscle cells. J Biol
Chem 281:8409–8416
76. Blottner D, Luck G (2001) Just in time and place: NOS/NO
system assembly in neuromuscular junction formation. Microsc
Res Tech 55:171–180
77. Godfrey EW, Schwarte RC (2003) The role of nitric oxide
signaling in the formation of the neuromuscular junction. J
Neurocytol 32:591–602
78. Senter L et al (1995) Phosphorylation of dystrophin: effects on
actin binding. Biochem Biophys Res Commun 206:57–63
79. Nelson RJ et al (1995) Behavioural abnormalities in male mice
lacking neuronal nitric oxide synthase. Nature 378:383–386
80. Chaubourt E et al (2000) The NO way to increase muscular
utrophin expression? C R Acad Sci III 323:735–740
81. Chaubourt E et al (1999) Nitric oxide and -arginine cause an
accumulation of utrophin at the sarcolemma: a possible com-
pensation for dystrophin loss in Duchenne muscular dystrophy.
Neurobiol Dis 6:499–507
82. Voisin V et al (2005) l-Arginine improves dystrophic phenotype
in mdx mice. Neurobiol Dis 20:123–130
83. Alderton JM, Steinhardt RA (2000) Calcium influx through
calcium leak channels is responsible for the elevated levels of
calcium-dependent proteolysis in dystrophic myotubes. J Biol
Chem 275:9452–9460
84. Whitehead NP et al (2006) Muscle damage in mdx (dystrophic)
mice: role of calcium and reactive oxygen species. Clin Exp
Pharmacol Physiol 33:657–662
85. Madhavan R et al (1992) Calmodulin specifically binds three
proteins of the dystrophin–glycoprotein complex. Biochem
Biophys Res Commun 185:753–759
86. Niebroj-Dobosz I et al (1989) Elevated calmodulin levels and
reduced calmodulin-stimulated calcium-ATPase in Duchenne
progressive muscular dystrophy. Neurology 39:1610–1614
87. Winder SJ, Kendrick-Jones J (1995) Calcium/calmodulin-depen-
dent regulation of the NH2-terminal F-actin binding domain of
utrophin. FEBS Lett 357:125–128
88. Calderilla-Barbosa L et al (2006) Phosphorylation of dystrophin
Dp71d by Ca2+/calmodulin-dependent protein kinase II modulates
the Dp71d nuclear localization in PC12 cells. J Neurochem 98:713–
722
89. Haghighi AP et al (2003) Retrograde control of synaptic
transmission by postsynaptic CaMKII at the Drosophila neuro-
muscular junction. Neuron 39:255–267
90. van der Plas MC et al (2006) Dystrophin is required for
appropriate retrograde control of neurotransmitter release at the
Drosophila neuromuscular junction. J Neurosci 26:333–344
91. Franco-Obregon A Jr, Lansman JB (1994) Mechanosensitive ion
channels in skeletal muscle from normal and dystrophic mice. J
Physiol 481(Pt 2):299–309
92. Constantin B et al (2006) New insights in the regulation of
calcium transfers by muscle dystrophin-based cytoskeleton:
implications in DMD. J Muscle Res Cell Motil 27:375–386
93. Bessou C et al (1998) Mutations in the Caenorhabditis elegans
dystrophin-like gene dys-1 lead to hyperactivity and suggest a
link with cholinergic transmission. Neurogenetics 2:61–72
94. Roberts RG, Bobrow M (1998) Dystrophins in vertebrates and
invertebrates. Hum Mol Genet 7:589–595
95. Gieseler K et al (2001) Molecular, genetic and physiological
characterisation of dystrobrevin-like (dyb-1) mutants of Caeno-
rhabditis elegans. J Mol Biol 307:107–117
96. Giugia J et al (1999) Mutations in the dystrophin-like dys-1 gene
of Caenorhabditis elegans result in reduced acetylcholinesterase
activity. FEBS Lett 463:270–272
97. Gieseler K et al (1999) Dystrobrevin- and dystrophin-like mutants
display similar phenotypes in the nematode Caenorhabditis
elegans. Neurogenetics 2:87–90
98. Kim H et al (2004) SNF-6 is an acetylcholine transporter
interacting with the dystrophin complex in Caenorhabditis
elegans. Nature 430:891–896
99. Meola G et al (1991) Growth and differentiation of myogenic
clones from adult human muscle cell cultures. Eur J Basic Appl
Histochem 35:219–231
100. Neuman S et al (2001) The dystrophin/utrophin homologues in
Drosophila and in sea urchin. Gene 263:17–29
101. NeumanSetal(2005)TheDrosophilahomologueofthedystrophin
gene—introns containing promoters are the major contributors to
the large size of the gene. FEBS Lett 579:5365–5371
102. Wairkar YP et al (2008) Synaptic defects in a Drosophila model
of congenital muscular dystrophy. J Neurosci 28:3781–3789
103. Bogdanik L et al (2008) Muscle dystroglycan organizes the
postsynapse and regulates presynaptic neurotransmitter release at
the Drosophila neuromuscular junction. PLoS ONE 3:e2084
104. Frank CA et al (2006) Mechanisms underlying the rapid
induction and sustained expression of synaptic homeostasis.
Neuron 52:663–677
105. Keshishian H, Kim YS (2004) Orchestrating development and
function: retrograde BMP signaling in the Drosophila nervous
system. Trends Neurosci 27:143–147
106. Christoforou CP et al (2008) The detached locus encodes
Drosophila dystrophin, which acts with other components of
the dystrophin associated protein complex to influence intercel-
lular signalling in developing wing veins. Dev Biol 313:519–532
107. DiAntonio A (2006) Glutamate receptors at the Drosophila
neuromuscular junction. Int Rev Neurobiol 75:165–179
108. Takahashi T (2005) Postsynaptic receptor mechanisms underly-
ing developmental speeding of synaptic transmission. Neurosci
Res 53:229–240
109. Jacobson C et al (1998) alpha-Dystroglycan functions in
acetylcholine receptor aggregation but is not a coreceptor for
agrin–MuSK signaling. J Neurosci 18:6340–6348
110. al-Qudah AA et al (1990) Etiology of intellectual impairment in
Duchenne muscular dystrophy. Pediatr Neurol 6:57–59
111. Bresolin N et al (1994) Cognitive impairment in Duchenne
muscular dystrophy. Neuromuscul Disord 4:359–369
112. Rae C et al (1998) Brain biochemistry in Duchenne muscular
dystrophy: a 1H magnetic resonance and neuropsychological
study. J Neurol Sci 160:148–157
113. Jagadha V, Becker LE (1988) Brain morphology in Duchenne
muscular dystrophy: a Golgi study. Pediatr Neurol 4:87–92
114. Septien L et al (1991) Mental development in Duchenne
muscular dystrophy. Correlation of data of the brain scanner.
Pediatrie 46:817–819
115. Yoshioka M et al (1980) Central nervous system involvement in
progressive muscular dystrophy. Arch Dis Child 55:589–594
116. Nakamura A et al (2008) Various central nervous system
involvements in dystrophinopathy: clinical and genetic consid-
erations. No To Hattatsu 40:10–14
117. Zimprich A et al (2001) Mutations in the gene encoding ε-
sarcoglycan cause myoclonus–dystonia syndrome. Nat Genet
29:66–69
118. Moukhles H, Carbonetto S (2001) Dystroglycan contributes to
the formation of multiple dystrophin-like complexes in brain. J
Neurochem 78:824–834
119. D'Souza VN et al (1995) A novel dystrophin isoform is required
for normal retinal electrophysiology. Hum Mol Genet 4:837–842
120. Lidov HGWet al (1995) Dp140: a novel 140 kDa CNS transcript
from the dystrophin locus. Hum Mol Genet 4:329–335
121. Byers TJ et al (1993) An alternative dystrophin transcript
specific to peripheral nerve. Nature Genet 4:77–81
122. Richard CA et al (1995) Cloning and characterization of
alternatively spliced isoforms of Dp71. Hum Mol Genet
4:1475–1483
Mol Neurobiol (2010) 41:1–21 19123. Moizard MP et al (2000) Severe cognitive impairment in DMD:
obvious clinical indication for Dp71 isoform point mutation
screening. Eur J Hum Genet 8:552–556
124. Lidov HG, Kunkel LM (1997) Dp140: alternatively spliced
isoforms in brain and kidney. Genomics 45:132–139
125. Bardoni A et al (1999) Absence of brain Dp140 isoform and
cognitive impairment in Becker muscular dystrophy. Lancet
353:897–898
126. Felisari G et al (2000) Loss of Dp140 dystrophin isoform and
intellectual impairment in Duchenne dystrophy. Neurology
55:559–564
127. Muntoni F et al (1991) Passive avoidance behaviour deficit in
the mdx mouse. Neuromuscul Disord 1:121–123
128. Sesay AK et al (1996) Spatial learning and hippocampal long-
term potentiation are not impaired in mdx mice. Neurosci Lett
211:207–210
129. Vaillend C et al (1998) Spatial discrimination learning and CA1
hippocampal synaptic plasticity in mdx and mdx3cv mice
lacking dystrophin gene products. Neurosci 86:53–66
130. Vaillend C et al (2004) Impaired long-term spatial and recognition
memory and enhanced CA1 hippocampal LTP in the dystrophin-
deficient Dmd(mdx) mouse. Neurobiol Dis 17:10–20
131. Bozon B et al (2003) MAPK, CREB and zif268 are all required
for the consolidation of recognition memory. Philos Trans R Soc
Lond B Biol Sci 358:805–814
132. Genoux D et al (2002) Protein phosphatase 1 is a molecular
constraint on learning and memory. Nature 418:970–975
133. Sekiguchi M et al (2009) A deficit of brain dystrophin impairs
specific amygdala GABAergic transmission and enhances
defensive behaviour in mice. Brain 132:124–135
134. Grady RM et al (2006) Cerebellar synaptic defects and abnormal
motor behavior in mice lacking alpha- and beta-dystrobrevin. J
Neurosci 26:2841–2851
135. Lidov HG (1996) Dystrophin in the nervous system. Brain
Pathol 6:63–77
136. Lidov HG et al (1990) Localization of dystrophin to postsynaptic
regions of central nervous system cortical neurons. Nature
348:725–728
137. Knuesel I et al (1999) Short communication: altered synaptic
clustering of GABAA receptors in mice lacking dystrophin (mdx
mice). Eur J NeuroSci 11:4457–4462
138. Miranda R et al (2009) Reorganization of inhibitory synapses
and increased PSD length of perforated excitatory synapses in
hippocampal area CA1 of dystrophin-deficient mdx mice. Cereb
Cortex 19:876–888
139. Pinto ML et al (2008) Loss of neuronal projections in the
dystrophin-deficient mdx mouse is not progressive. Brain Res
1224:127–132
140. Kueh SL et al (2008) GABA(A) receptor expression and
inhibitory post-synaptic currents in cerebellar Purkinje cells in
dystrophin-deficient mdx mice. Clin Exp Pharmacol Physiol
35:207–210
141. Brunig I et al (2002) GABAergic terminals are required for
postsynaptic clustering of dystrophin but not of GABA(A)
receptors and gephyrin. J Neurosci 22:4805–4813
142. Levi S et al (2002) Dystroglycan is selectively associated with
inhibitory GABAergic synapses but is dispensable for their
differentiation. J Neurosci 22:4274–4285
143. Anderson JL et al (2003) Altered inhibitory input to Purkinje
cells of dystrophin-deficient mice. Brain Res 982:280–283
144. Anderson JL et al (2004) Long-term depression is reduced in
cerebellar Purkinje cells of dystrophin-deficient mdx mice. Brain
Res 1019:289–292
145. Graciotti L et al (2008) GABAergic miniature spontaneous
activity is increased in the CA1 hippocampal region of
dystrophic mdx mice. Neuromuscul Disord 18:220–226
146. Vaillend C, Billard JM (2002) Facilitated CA1 hippocampal
synaptic plasticity in dystrophin-deficient mice: role for GABAA
receptors? Hippocampus 12:713–717
147. Moore SA et al (2002) Deletion of brain dystroglycan recapit-
ulates aspects of congenital muscular dystrophy. Nature
418:422–425
148. Gerlai R (1998) A new continuous alternation task in T-maze
detects hippocampal dysfunction in mice. A strain comparison
and lesion study. Behav Brain Res 95:91–101
149. Gerlai R et al (1998) Multiple behavioral anomalies in GluR2
mutant mice exhibiting enhanced LTP. Behav Brain Res 95:37–45
150. Gerlai R et al (1998) Altered spatial learning and memory in
mice lacking the mGluR4 subtype of metabotropic glutamate
receptor. Behav Neurosci 112:525–532
151. Migaud M et al (1998) Enhanced long-term potentiation and
impaired learning in mice with mutant postsynaptic density-95
protein. Nature 396:433–439
152. Daoud F et al (2009) Role of mental retardation-associated
dystrophin-gene product Dp71 in excitatory synapse organization,
synapticplasticity andbehavioral functions.PLoS ONE 4(8):e6574
153. Fradkin LG et al (2008) The dystrophin Dp186 isoform regulates
neurotransmitter release at a central synapse in Drosophila. J
Neurosci 28:5105–5114
154. Cibis GW et al (1993) The effects of dystrophin gene mutations
on the ERG in mice and humans. Invest Ophthalmol Vis Sci
34:3646–3652
155. Pillers DA et al (1993) Dystrophin expression in the human
retina is required for normal function as defined by electroret-
inography. Nature Genet 4:82–86
156. Tamura T et al (1993) Dystrophin isoforms expressed in the
mouse retina. J Neurol Sci 115:214–218
157. Howard PL et al (1998) Localization of dystrophin isoform Dp71
to the inner limiting membrane of the retina suggests a unique
functional contribution of Dp71 in the retina. Hum Mol Genet
7:1385–1391
158. Claudepierre T et al (1999) Differential distribution of dystro-
phins in rat retina. Invest Opthamol Vis Sci 40:1520–1529
159. Pillers D-AM et al (1999) Duchenne/Becker muscular dystrophy:
correlation of phenotype by electroretinography with sites of
dystrophin mutations. Hum Genet 105:2–9
160. Jastrow H et al (2006) Identification of a beta-dystroglycan
immunoreactive subcompartment in photoreceptor terminals.
Invest Ophthalmol Vis Sci 47:17–24
161. Schmitz F, Drenckhahn D (1997) Dystrophin in the retina. Prog
Neurobiol 53:547–560
162. Schmitz F, Drenckhahn D (1997) Localization of dystrophin and
beta-dystroglycan in bovine retinal photoreceptor processes
extending into the postsynaptic dendritic complex. Histochem
Cell Biol 108:249–255
163. Ueda H et al (1997) Dystrophin in rod spherules; submembra-
nous dense regions facing bipolar cell processes. Histochem Cell
Biol 108:243–248
164. Fitzgerald KM et al (1994) Retinal signal transmission in
Duchenne muscular dystrophy: evidence for dysfunction in the
photoreceptor/depolarizing bipolar cell pathway. J Clin Invest
93:2425–2430
165. Green DG et al (2004) Normal photoresponses and altered b-
wave responses to APB in the mdx(Cv3) mouse isolated retina
ERG supports role for dystrophin in synaptic transmission. Vis
Neurosci 21:739–747
166. Fort PE et al (2008) Kir4.1 and AQP4 associate with Dp71- and
utrophin-DAPs complexes in specific and defined microdomains
of Muller retinal glial cell membrane. Glia 56:597–610
167. Dalloz C et al (2003) Targeted inactivation of dystrophin gene
product Dp71: phenotypic impact in mouse retina. Hum Mol
Genet 12:1543–1554
20 Mol Neurobiol (2010) 41:1–21168. Costa MF et al (2007) Red–green color vision impairment in
Duchenne muscular dystrophy. Am J Hum Genet 80:1064–1075
169. Sato S et al (2008) Pikachurin, a dystroglycan ligand, is essential
for photoreceptor ribbon synapse formation. Nat Neurosci
11:923–931
170. Garrity PA et al (1996) Drosophila photoreceptor axon guidance
and targeting requires the dreadlocks SH2/SH3 adapter protein.
Cell 85:639–650
171. Song J et al (2003) Axons guided by insulin receptor in
Drosophila visual system. Science 300:502–505
172. Willmann R et al (2009) Mammalian animal models for
Duchenne muscular dystrophy. Neuromuscul Disord 19:241–249
173. Thomson AM, Deuchars J (1997) Synaptic interactions in
neocortical local circuits: dual intracellular recordings in vitro.
Cereb Cortex 7:510–522
174. Zucker RS, Regehr WG (2002) Short-term synaptic plasticity.
Ann Rev Physiol 64:355–405
175. Bliss TVP, Lomo T (1973) Long-lasting potentiation of synaptic
transmission in the dentate area of the anaesthetized rabbit
following stimulation of the perforant path. J Physiol 232:331–
356
176. Bear MF, Abraham WC (1996) Long-term depression in
hippocampus. Ann Rev Neurosci 19:437–462
177. Kombian SB et al (2000) Short-term potentiation of miniature
excitatory synaptic currents causes excitation of supraoptic
neurons. J Neurophysiol 83:2542–2553
178. Wu Yet al (2005) Properties of short-term synaptic depression at
larval neuromuscular synapses in wild-type and temperature-
sensitive paralytic mutants of Drosophila. J Neurophysiol
93:2396–2405
179. Schiller PH et al (1986) Functions of the ON and OFF channels
of the visual system. Nature 322:824–825
180. Guyon JR et al (2003) The dystrophin associated protein
complex in zebrafish. Hum Mol Genet 12:601–615
181. Böhm S et al (2008) Dystrobrevin and dystrophin family gene
expression in zebrafish. Gene Expr Patterns 8:71–78
182. Fort P et al (2005) The sarcoglycan–sarcospan complex
localization in mouse retina is independent from dystrophins.
Neurosci Res 53:25–33
183. Ishikawa-Sakurai M et al (2004) ZZ domain is essentially
required for the physiological binding of dystrophin and utrophin
to β-dystroglycan. Hum Mol Genet 13:693–702
184. Balasubramanian S et al (1998) Characterization of the tyrosine
phosphorylation and distribution of dystrobrevin isoforms. FEBS
Lett 432:133–140
185. Peters MF et al (1998) Differential membrane localization and
intermolecular associations of alpha-dystrobrevin isoforms in
skeletal muscle. J Cell Biol 142:1269–1278
186. Crosbie RH et al (2000) Molecular and genetic characterization
of sarcospan: insights into sarcoglycan–sarcospan interactions.
Hum Mol Genet 9:2019–2027
187. Ohlendieck K et al (1991) Dystrophin-related protein is localized to
neuromuscularjunctionsofadultskeletalmuscle.Neuron7:499–508
188. Peng HB et al (1999) Acetylcholinesterase clustering at the
neuromuscular junction involves perlecan and dystroglycan. J
Cell Biol 145:911–921
189. Fuhrer C et al (1999) Roles of rapsyn and agrin in interaction of
postsynaptic proteins with acetylcholine receptors. J Neurosci
19:6405–6416
190. Gautam M et al (1995) Failure of postsynaptic specialization to
develop at neuromuscular junctions of rapsyn-deficient mice.
Nature 377:232–236
191. Claudepierre T et al (2000) Characterization of the intermolec-
ular associations of the dystrophin-associated glycoprotein
complex in retinal Muller glial cells. J Cell Sci 113:3409–3417
192. Rurak J et al (2007) Distribution of potassium ion and water
permeable channels at perivascular glia in brain and retina of the
Large(myd) mouse. J Neurochem 103:1940–1953
Mol Neurobiol (2010) 41:1–21 21